

Original articles

1987

Weller M, Wiedemann P, Heimann K. Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro. *Graefe's Arch Clin Exp Ophthalmol* 1987;225:235-238

1988

Ginns EI, Rehavi M, Martin BM, Weller M, O'Malley KL, LaMarca ME, McAllister CG, Paul SM. Expression of human tyrosine hydroxylase cDNA in invertebrate cells using a baculovirus vector. *J Biol Chem* 1988;263:7406-7410

Weller M, Heimann K, Wiedemann P. Demonstration of mononuclear phagocytes in a human epiretinal membrane using a monoclonal anti-human macrophage antibody. *Graefe's Arch Clin Exp Ophthalmol* 1988;226:252-254

Weller M, Heimann K, Wiedemann P. Immunochemical studies of epiretinal membranes using APAAP complexes: evidence for macrophage involvement in traumatic proliferative vitreoretinopathy. *Int Ophthalmol* 1988;11:181-186

Weller M, Wiedemann P, Heimann K, Zilles K. Fibronectin quantification in plasma and vitreous by a noncompetitive ELISA technique. *Doc Ophthalmol* 1988;69:341-351

Weller M, Wiedemann P, Heimann K, Zilles K. The significance of fibronectin in vitreoretinal pathology: a critical evaluation. *Graefe's Arch Clin Exp Ophthalmol* 1988;226:294-298

Wiedemann P, Weller M, Heimann K. Traktionsamotio bei Morbus Coats. *Klin Monatsbl Augenheilkd* 1988;193:200-201

Weller M, Fischbach R, Heimann K, Wiedemann P. Zur Bedeutung der Fibronectine bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1988;85:263-266

Weller M, Heimann K, Wiedemann P. L'importance des macrophages et de la fibronectine pour la prolifération vitréo-rétinienne. *J Fr Ophtalmol* 1988;11:243-247

Weller M, Wiedemann P, Fischbach R, Hartmann C, Heimann K. Evaluation of daunomycin toxicity on lens epithelium in vitro. *Int Ophthalmol* 1988;12:127-130

1989

Weller M, Wiedemann P, Moter H, Heimann K. Transferrin and transferrin receptor expression in proliferative intraocular disease. APAAP labeling and ELISA for vitreal transferrin. *Graefe's Arch Clin Exp Ophthalmol* 1989;227:281-286

Weller M, Heimann K, Wiedemann P. Immunhistochemische Befunde bei proliferativen Netzhauterkrankungen. Zur Bedeutung von Fibronectin, Makrophagen und Transferrin. *Fortschr Ophthalmol* 1989;86:121-123

Hartmann C, Wiedemann P, Weller M, Pharmakakis N, Heimann K. In Vitro Veränderungen des Linsenepithels und Hornhautendothels durch das Zytostatikum Daunomycin. *Fortschr Ophthalmol* 1989;86:167-171

Moter H, Wiedemann P, Weller M, Heimann K. Isoelektrische Fokussierung von Glaskörperproteinen. *Fortschr Ophthalmol* 1989;86:399-402

Weller M, Bresgen M, Heimann K, Wiedemann P. Zur Immunhistologie der proliferativen Vitreoretinopathie nach Riesenriss-Amotio. *Klin Monatsbl Augenheilkd* 1989;195:323-325

1990

Hartmann C, Wiedemann P, Gothe K, Weller M, Heimann K. Prévention de la cataracte secondaire par application endocapsulaire de l'antimitotique daunomycine. *Ophthalmologie* 1990;4:102-106

Weller M, Wiedemann P, Bresgen M, Heimann K. Giant preretinal fibrin membrane formation behind a silicone oil bubble in a hypotensive eye. *Retina* 1990;10:86-91

Weller M, Wiedemann P, Bresgen M, Heimann K. Vitronectin: Mediator der Zelladhäsion bei der proliferativen Vitreoretinopathie. *Fortschr Ophthalmol* 1990;87:221-225

Bresgen M, Weller M, Heimann K, Wiedemann P. Nachweis von Blutgerinnungsfaktor XIII im Glaskörper und periretinalen Membranen bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1990;87:279-282

Clausen R, Weller M, Hilgers RD, Heimann K, Wiedemann P. Quantitative Bestimmung von sechs Glaskörperproteinen im normalen Glaskörper und bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1990;87:283-286

Moter H, Weller M, Heimann K, Wiedemann P. Laktoferrin und Transferrin. Eisenbindende Proteine in physiologischem und pathologischem Glaskörper. *Fortschr Ophthalmol* 1990;87:336-339

Esser P, Weller M, Heimann K, Wiedemann P. Vitronectin- und Fibronectinrezeptoren bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1990;87:344-347

Weller M, Bresgen M, Heimann K, Wiedemann P. Blood coagulation factor XIII contributes to the development of periretinal membranes. *Acta Ophthalmol* 1990;68:246-252

Weller M, Clausen R, Heimann K, Wiedemann P. Iron-binding proteins in the human vitreous. Lactoferrin and transferrin in health and in proliferative intraocular disease. *Ophthalmic Res* 1990;22:194-200

Weller M, Clausen R, Bresgen M, Heimann K, Wiedemann P. Immunoglobulin G, complement factor C3 and lymphocytes in proliferative intraocular disorders. *Int Ophthalmol* 1990;14:277-283

Weller M, Poremba M, Dichgans J. Opercular syndrome without opercular lesions: Foix-Chavany-Marie syndrome in progressive supranuclear motor system degeneration. *Eur Arch Psychiatr Clin Neurosci* 1990;239:370-372

Weller M, Sommer N, Stevens A, Wiethölter H. Increased intrathecal synthesis of fibronectin in bacterial and carcinomatous meningitis. *Acta Neurol Scand* 1990;82:138-142

Weller M, Sommer N, Stevens A, Wiethölter H. Zur klinischen Bedeutung der Fibronectinbestimmung im Liquor. *Aktuel Neurol* 1990;17:187-189

1991

Weller M, Wiedemann P, Bresgen M, Heimann K. Vitronectin and proliferative intraocular disorders. I. A colocalization study of the serum spreading factor, vitronectin, and fibronectin in periretinal membranes. *Int Ophthalmol* 1991;15:93-101

Weller M, Wiedemann P, Bresgen M, Heimann K. Vitronectin and proliferative intraocular disorders. II. Expression of cell surface receptors for fibronectin and vitronectin in periretinal membranes. *Int Ophthalmol* 1991;15:103-108

Clausen R, Weller M, Wiedemann P, Heimann K, Hilgers RD, Zilles K. An immunochemical quantitative analysis of the protein pattern in physiological and pathologic vitreous. *Graefes Arch Clin Exp Ophthalmol* 1991;229:186-190

Weller M, Esser P, Heimann K, Wiedemann P. Retinal microglia: a new cell in idiopathic proliferative vitreoretinopathy. *Exp Eye Res* 1991;53:275-281

Esser P, Weller M, Heimann K, Wiedemann P. Thrombospondin und seine Bedeutung bei proliferativen Netzhauterkrankungen. *Fortschr Ophthalmol* 1991;88:337-340

Bresgen M, Martiny B, Weller M, Heimann K, Wiedemann P. Analyse des Proteinmusters in physiologischen und pathologischen Glaskörpern durch Elektrophorese und immunologische Identifizierung. *Fortschr Ophthalmol* 1991;88:665-670

Grisanti S, Wiedemann P, Weller M, Heimann K, Zilles K. The significance of complement in proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci* 1991 ;32 :2711-2717

Weller M, Leo-Kottler B, Berg PA, Wiethölter H. Effective suppression of crescendo amaurosis fugax associated with antiphospholipid antibodies by low dose aspirin. *Neuroophthalmology* 1991;11:195-197

Wilhelm H, Weller M, Wiethölter H, Schiefer U. Ross-Syndrom: Adie-Syndrom mit Störungen der Schweiß- und Temperaturregulation. *Klein Monatsbl Augenheilkd* 1991;199:442-443

Weller M, Stevens A, Sommer N, Melms A, Dichgans J, Wiethölter H. Comparative analysis of cytokine patterns in immunologic, inflammatory, and oncological neurological disorders. *J Neurol Sci* 1991;104:215-221

Weller M, Stevens A, Sommer N, Wiethölter H, Dichgans J. CSF interleukins, immunoglobulins, and fibronectin in neuroborreliosis. *Arch Neurol* 1991;48:837-841

Sommer N, Weller M, Petersen D, Wiethölter H, Dichgans J. Neurosarcoidosis without systemic sarcoidosis. *Eur Arch Psychiatr Clin Neurosci* 1991;240:334-338

Weller M, Leo-Kottler B, Berg PA, Wiethölter H. Antiphospholipidsyndrom: Neurologische Komplikationen und therapeutische Möglichkeiten. *Dtsch Med Wschr* 1991;116:1794-1796, *DMW Japan* 1991;13:1653-1655

Kornhuber J, Weller M. Post-partum psychosis and mastitis: a new indication for clozapine? *Am J Psychiatry* 1991;148:1751-1752

1992

Esser P, Weller M, Bresgen M, Heimann K, Wiedemann P. The effects of basic fibroblast growth factor on bovine retinal pigment epithelium in vitro. *German J Ophthalmol* 1992;1:58-61

Weller M, Esser P, Bresgen M, Heimann K, Wiedemann P. Thrombospondin: a new attachment protein in preretinal traction membranes. *Eur J Ophthalmol* 1992;2:10-14

Molitor R, Esser P, Weller M, Wiedemann P, Heimann K. Kontraktile Elemente bei proliferativen Netzhauterkrankungen. *Ophthalmologie* 1992;89:34-38

Grisanti S, Esser P, Weller M, Wiedemann P, Heimann K. Die proliferative Vitreoretinopathie. Aktivierung des Komplementsystems. *Ophthalmologie* 1992;89:50-54

Weller M, Esser P, Heimann K, Wiedemann P. Die idiopathische proliferative Vitreoretinopathie. Die Aktivierung von Mikrogliazellen als entscheidender Faktor. *Ophthalmologie* 1992;89:387-390

Wiethölter H, Schabet M, Stevens A, Melms A, Sommer N, Weller M. Influence of gangliosides on experimental allergic neuritis. *J Neuroimmunol* 1992;38:221-228

Weller M, Stevens A, Sommer N, Wiethölter H. Tumor necrosis factor- α in malignant melanomatous meningitis. *J Neurol Neurosurg Psychiatry* 1992;55:74

- Weller M, Liedtke W, Petersen D, Opitz H, Poremba M. Very late onset adrenoleukodystrophy. Possible precipitation of demyelination by cerebral contusion. *Neurology* 1992;42:367-370
- Weller M, Stevens A, Sommer N, Wiethölter H. Intrathekale Immunantwort bei Meningeosis neoplastica. IgG, IgM, oligoklonale Banden und Zytokine. *Nervenarzt* 1992;63:213-217
- Liedtke W, Weller M, Wiethölter H, Dichgans J. Immunological abnormalities in the tears of multiple sclerosis patients. *Acta Neurol Scand* 1992;85:228-230
- Weller M, Stevens A, Sommer N, Schabet M, Wiethölter H. Tumor cell dissemination triggers an intrathecal immune response in neoplastic meningitis. *Cancer* 1992;69:1475-1480
- Eblen F, Weller M, Dichgans J. Automatic-voluntary dissociation: an unusual facial paresis in a patient with probable multiple sclerosis. *Eur Arch Psychiatr Clin Neurosci* 1992;242:93-95
- Weller M, Stevens A, Sommer N, Dichgans J, Kappler B, Wiethölter H. Ganglioside antibodies: a lack of diagnostic specificity and clinical utility? *J Neurol* 1992;239:455-459
- Weller M, Stevens A, Sommer N, Wiethölter H. Are CSF or serum ganglioside antibodies related to peripheral nerve demyelination in neuroborreliosis, Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy? *Eur Arch Psychiatr Clin Neurosci* 1992;242:122-126
- Weller M, Stevens A, Sommer N, Schabet M, Wiethölter H. Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia. *Acta Neurol Scand* 1992;86:129-133
- Stevens A, Weller M, Wiethölter H. CSF and serum ganglioside antibody patterns in MS. *Acta Neurol Scand* 1992;86:485-489
- Becker T, Hoffmann E, Struck M, Weller M, Sperling W, Lanczik M. Marchiafava-Bignami-Syndrom: CT- und MR-Befunde in einem atypischen Fall. *Klin Neuroradiol* 1992;2:24-27
- Weller M, Kornhuber J, Beckmann H. Elektrokonvulsionstherapie zur Behandlung der akuten lebensbedrohlichen Katatonie bei toxischer epidermaler Nekrolyse (Lyell-Syndrom). *Nervenarzt* 1992;63:308-310
- Weller M, Müller U, Kornhuber J. Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence? *J Clin Psychiatry* 1992;53:257-258
- Weller M, Kornhuber J. Differentielle Neuroleptie bei schizophrenen Psychosen im Wochenbett: Vorteile des atypischen Neuroleptikums Clozapin. *Nervenarzt* 1992;63:440-441
- Weller M, Kornhuber J. Lyell syndrome and lethal catatonia: a case for ECT. *Am J Psychiatry* 1992;149:1114
- Weller M, Kornhuber J. Clozapine rechallenge after an episode of "neuroleptic malignant syndrome". *Br J Psychiatry* 1992;161:855-856 (Comment in: 1993;162:566 and 1993;163:121-122)
- Weller M, Kornhuber J. ECT in a geriatric patient with multiple bony fractures and generalized plasmacytoma. *Pharmacopsychiatry* 1992;25:278-280
- Becker T, Kornhuber J, Hofmann E, Weller M, Rupprecht C, Beckmann H. MRI white matter hyperintensity in neuroleptic malignant syndrome - a clue to pathogenesis? *J Neural Transmission [Gen Sect]* 1992;90:151-159
- Stevens A, Weller M. Ganglioside antibody patterns in schizophrenia and major depression. *Biol Psychiatry* 1992;32:728-730
- Weller M, Marini AM, Paul SM. Niacinamide blocks 3-acetylpyridine toxicity of cerebellar granule cells

in vitro. Brain Res 1992;594:160-164

1993

Stevens A, Weller M, Wiethölter H. A characteristic ganglioside antibody pattern in the CSF of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 1993;56:361-364

Weller M, Stevens A, Sommer N, Wiethölter H. Intrathecal IgM response in disseminated cerebrospinal metastasis from malignant melanoma. J Neuro-Oncol 1993;16:55-59

Müller U, Warmuth-Metz M, Weller M, Hönes S, Becker T. Intrakranielle Epidermoide und Dermoide in der Psychiatrie. Drei Fallbeispiele und Literaturübersicht. Neuropsychiatrie 1993;7:138-146

Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transmission [Gen Sect] 1993;92:57-65

Weller M, Kornhuber J. Clozapin: Risikoneuroleptikum für die Auslösung eines malignen neuroleptischen Syndroms (MNS) oder neuroleptische Alternative bei positiver MNS-Anamnese? Fortschr Neurol Psychiatr 1993;61:217-222

Weller M, Kornhuber J. Serum iron levels in neuroleptic malignant syndrome. Biol Psychiatry 1993;34:123-124

Weller M, Finiels-Marlier F, Paul SM. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 1993;613:143-148

Montpied P, Weller M, Paul SM. N-methyl-D-aspartate receptor agonists decrease protooncogene *bcl-2* mRNA expression in cultured rat cerebellar granule neurons. Biochem Biophys Res Commun 1993;195:623-629

Weller M, Paul SM. 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. Eur J Pharmacol [Environmental Toxicol Pharmacol Sect] 1993;248:223-228

Weller M, Marini AM, Finiels-Marlier F, Martin B, Paul SM. MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. Eur J Pharmacol [Environmental Toxicol Pharmacol Sect] 1993;248:303-312

1994

Esser P, Bresgen M, Weller M, Heimann K, Wiedemann P. The significance of vitronectin in proliferative diabetic retinopathy. Graefe's Arch Clin Exp Ophthalmol 1994;32:477-481

Weller M, Montpied P, Paul SM. NMDA receptor-mediated excitoprotection of cultured cerebellar granule neurons fails to alter glutamate-induced expression of *c-fos* and *c-jun* mRNAs. Mol Brain Res 1994;22:227-235

Weller M, Marini AM, Martin B, Paul SM. The reduced unsubstituted pteroyl moiety is required for folate toxicity of cultured cerebellar granule neurons. J Pharmacol Exp Ther 1994;269:393-401

Yan GM, Ni B, Weller M, Wood KA, Paul SM. Depolarization or glutamate receptor activation blocks apoptotic cell death of cultured cerebellar granule neurons. Brain Res 1994;656:43-51

Weller M, Constam D, Malipiero U, Fontana A. Transforming growth factor- β 2 induces apoptosis of murine T cell clones without down-regulating *bcl-2* mRNA expression. Eur J Immunol 1994;24:1293-1300

Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-

mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines. *J Clin Invest* 1994;94:954-964

1995

Kornhuber J, Weller M. Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany. *Convulsive Therapy* 1995;11:104-109

Sommer N, Löschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmüller A, Dichgans J, Fontana A, Martin R. Cytokine-directed suppression of autoimmune encephalomyelitis by the antidepressant rolipram. *Nat Med* 1995;1:244-248

Weller M, Malipiero U, Groscurth P, Fontana A. T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor- β 2: modulation by the phosphatase inhibitors, okadaic acid and calyculin A. *Exp Cell Res* 1995;221:395-403

Weller M, Malipiero UV, Aguzzi A, Reed JC, Fontana A. Protooncogene *bcl-2* gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. *J Clin Invest* 1995;95:2633-2643

Weller M, Malipiero U, Rensing-Ehl A, Barr P, Fontana A. Fas/APO-1 gene transfer for human malignant glioma. *Cancer Res* 1995;55:2936-2944

Yan GM, Irwin RP, Lin SZ, Weller M, Wood KA, Paul SM. Diphenylhydantoin induces apoptotic cell death of cerebellar granule neurons. *J Pharmacol Exp Ther* 1995;274:983-990

Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A. Loco-regional Fas/APO-1 (CD95) ligand-mediated tumor cell killing *in vivo*. *Eur J Immunol* 1995;25:2253-2258

Esser P, Heimann K, Abts H, Fontana A, Weller M. CD95 (Fas/APO-1) antibody-mediated apoptosis of human retinal pigment epithelial cells. *Biochem Biophys Res Commun* 1995;213:1026-1034

Wüllner U, Löschmann PA, Weller M, Klockgether T. Apoptotic cell death in the cerebellum of mutant *weaver* and *lurcher* mice. *Neurosci Lett* 1995;200:109-112

1996

Esser P, Bartz-Schmidt KU, Walter P, Kaszli F, Heimann K, Weller M. Apoptotic cell death in proliferative vitreoretinopathy. *Ger J Ophthalmol* 1996;5:73-78

Weller M, Petersen D, Dichgans J, Klockgether T. Cerebral angiography complications link cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy to familial hemiplegic migraine. *Neurology* 1996;46:844

Bingisser R, Stey C, Weller M, Groscurth P, Russi E, Frei K. Apoptosis in human alveolar macrophages is induced by endotoxin and is modulated by cytokines. *Am J Resp Cell Mol Biol* 1996;15:64-70

Trepel M, Weller M, Petersen D, Dichgans J. Voluntary facial palsy with a pontine lesion. *J Neurol Neurosurg Psychiatry* 1996;61:531-533

De Luca A, Weller M, Fontana A. TGF- β -induced apoptosis of cerebellar granule neurons is prevented by depolarization. *J Neurosci* 1996;16:4174-4185

Schulz JB, Weller M, Klockgether T. Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. *J Neurosci* 1996;16:4696-4706

De Luca A, Weller M, Frei K, Fontana A. Maturation-dependent modulation of apoptosis in cultured cerebellar granule neurons by cytokines and neurotrophins. *Eur J Neurosci* 1996;8:1994-2005

1997

Weller M, Heimann K, Bartz-Schmidt KU, Fontana A, Esser P. CD95 expression in traumatic proliferative vitreoretinopathy: a target for the induction of apoptosis. *Ger J Ophthalmol* 1997;5:332-337

Esser P, Heimann K, Bartz-Schmidt KU, Fontana A, Weller M. Apoptosis in proliferative vitreoretinal disorders. Possible involvement of TGF- β -induced RPE cell apoptosis. *Exp Eye Res* 1997;65:365-378

Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? *Neurology* 1997;48:1704-1709

Roth W, Fontana A, Trepel M, Dichgans J, Reed JC, Weller M. Immunotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. *Cancer Immunol Immunother* 1997;44:55-63

Esser P, Heimann K, Bartz-Schmidt KU, Walter P, Krott R, Weller M. Plasminogen in proliferative vitreoretinal disorders. *Br J Ophthalmol* 1997;81:590-594

Klockgether T, Weller M, Haarmeier T, Kaskas B, Maier G, Dichgans J. Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. *Neurology* 1997;48:275-276

Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J. Ocular myasthenia gravis: response to long term immunosuppressive treatment. *J Neurol Neurosurg Psychiatry* 1997;62:156-162

Wagenknecht B, Gulbins E, Lang F, Dichgans J, Weller M. Lipxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. *FEBS Lett* 1997;409:17-23

Wüllner U, Weller M, Groscurth P, Löschmann PA, Schulz JB, Müller I, Klockgether T. Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: the effects of 3-acetylpyridine neurotoxicity. *Neuroscience* 1997;81:721-734

Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S, Reed JC. Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. *Neurol Res* 1997;19:459-470

Wagenknecht B, Trepel M, Von Deimling A, Grimmel C, Rollbrocker B, Hayashi Y, Lang F, Dichgans J, Gulbins J, Weller M. p53 accumulation promotes dephosphorylation and proteolytic cleavage of retinoblastoma protein in human malignant glioma cells. *Cell Physiol Biochem* 1997;7:304-311

Weller M, Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F, Gulbins E. CD95-dependent T cell killing by glioma cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. *Cell Physiol Biochem* 1997;7:282-288

Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH, Weller M. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. *J Immunol* 1997;159:2108-2115

Esser P, Grisanti S, Kociok N, Abts H, Hueber A, Unfried K, Heimann K, Weller M. Expression and up-regulation of MAP1B in cultured retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci* 1997;38:2852-2856

Schulz JB, Bremen D, Reed JC, Lommatzsch J, Takayama S, Wüllner U, Löschmann PA, Klockgether T, Weller M. Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species. *J Neurochem* 1997;69:2075-

Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P. Topoisomerase I inhibitors for human malignant glioma. Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β -lapachone. *Int J Cancer* 1997;73:707-714

Trepel M, Scheduling S, Groscurth P, Horny HP, Malipiero U, Brugger W, Dichgans J, Weller M. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. *Leukemia* 1997;11:1842-1849

1998

Ständer M, Dichgans J, Weller M. Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells. *J Neuro-Oncol* 1998;37:191-198

Hueber A, Winter S, Weller M. Chemotherapy primes malignant glioma cells for CD95L-induced apoptosis. *Eur J Pharmacol* 1998;352:111-115

Roth W, Wagenknecht B, Grimm C, Dichgans J, Weller M. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells is independent of p53 induction and G2/M cell cycle arrest. *Br J Cancer* 1998;77:404-411

Weller M, Dichgans J, Klockgether T. Acetazolamide-responsive migraine in CADASIL. *Neurology* 1998;50:1505

Esser P, Tervooren D, Heimann K, Kociok N, Bartz-Schmidt KU, Walter P, Weller M. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci* 1998;39:164-170

Zipp F, Faber E, Sommer N, Müller C, Dichgans J, Krammer PH, Martin R, Weller M. CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. *J Neuroimmunol* 1998;81:168-172

Reber U, Wüllner U, Trepel M, Baumgart J, Seyfried J, Klockgether T, Dichgans J, Weller M. Potentiation of treosulfan toxicity by the glutathione-depleting agent, buthionine sulfoximine, in human malignant glioma cells: the role of bcl-2. *Biochem Pharmacol* 1998;55:349-359

Brenner B, Ferlinz K, Weller M, Grassmé H, Koeppenhofer U, Dichgans J, Sandhoff K, Lang F, Gulbins E. Fas/CD95/APO-1 activates the acidic sphingomyelinase via caspases. *Cell Death Differ* 1998;5:29-37

Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. *J Neurol Sci* 1998;155:68-75

Weller M, Klockgether T. Minocycline-induced benign intracranial hypertension. *J Neurol* 1998;245:55

Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing remitting multiple sclerosis. *Ann Neurol* 1998;43:116-120

Winter S, Roth W, Dichgans J, Weller M. Synergistic activity of CD95 ligand and teniposide (VM26) does not involve enhanced formation of cleavable DNA complexes or changes in CD95/CD95 ligand expression. *Eur J Pharmacol* 1998;341:323-328

Gulbins E, Hermisson M, Brenner B, Grassmé HU, Linderkamp O, Dichgans J, Weller M, Lang F. Cellular stimulation via CD95 involves activation of phosphoinositide-3-kinase. *Pflügers Arch - Eur J Physiol* 1998;435:546-554

- Weller M, Bornemann A, Ständer M, Schabet M, Dichgans J, Meyermann R. Humoral immune response to p53 in malignant glioma. *J Neurol* 1998;245:169-172
- Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J, Weller M. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. *J Neuro-Oncol* 1998;39:19-32
- Abele M, Leonhardt M, Dichgans J, Weller M. CCNU overdose during PCV chemotherapy for anaplastic astrocytoma. *J Neurol* 1998;245:236-238
- Weller M, Schuster M, Pietsch T, Schabet M. CD95 ligand-induced apoptosis of human medulloblastoma cells. *Cancer Lett* 1998;128:121-126
- Wüllner U, Weller M, Schulz JB, Krajewski S, Reed JC, Klockgether T. Bcl-2, Bax, and Bcl-x expression in neuronal apoptosis: a study of mutant *weaver* and *lurcher* mice. *Acta Neuropathol* 1998;96:233-238
- Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M. Serum CD95 of multiple sclerosis patients protects from CD95-mediated apoptosis. *J Neuroimmunol* 1998;86:151-154
- Heneka M,T, Löschmann PA, Gleichmann M, Weller M, Schulz JB, Wüllner U, Klockgether T. Induction of nitric oxide synthase (iNOS) and NO-mediated apoptosis in neuronal PC12 cells after stimulation with TNF α /LPS. *J Neurochem* 1998;71:88-94
- Gleichmann M, Beinroth S, Reed JC, Krajewski S, Schulz JB, Wüllner U, Klockgether T, Weller M. Potassium deprivation-induced apoptosis of cerebellar granule neurons: cytochrome C release in the absence of altered expression of bcl-2 family proteins. *Cell Physiol Biochem* 1998;8:194-201
- Schulz JB, Beinroth S, Weller M, Wüllner U, Klockgether T. Endonucleolytic DNA fragmentation is not required for apoptosis of cerebellar granule neurons. *Neurosci Lett* 1998;245:9-12
- Roth W, Wagenknecht B, Dichgans J, Weller M. Interferon- α enhances CD95L-induced apoptosis of human malignant glioma cells. *J Neuroimmunol* 1998;87:121-129
- Naumann U, Weller M. Retroviral bax gene transfer fails to sensitize malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy. *Int J Cancer* 1998;77:645-648
- Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann PA, Gulbins E, Dichgans J, Weller M. Decorin gene-transfer mediated suppression of TGF- β synthesis abrogates experimental malignant glioma growth in vivo. *Gene Therapy* 1998;5:1187-1194
- Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? *FEBS Lett* 1998;427:124-128
- Winter S, Weller M. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L expression. *J Pharmacol Exp Ther* 1998;286:1374-1382
- Schulz JB, Weller M, Matthews RT, Heneka MT, Groscurth P, Martinou JC, Lommatzsch J, von Coelln R, Wüllner U, Löschmann PA, Beal MF, Dichgans J, Klockgether T. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. *Cell Death Differ* 1998;5:847-857
- Naumann U, Durka S, Weller M. Dexamethasone-mediated protection from drug toxicity linked to p21^{WAF/CIP1} protein accumulation. *Oncogene* 1998;17:1567-1575
- Hueber A, Esser P, Heimann K, Kociok N, Schraermeyer U, Winter S, Weller M. The topoisomerase I inhibitors, camptothecin and β -lapachone, induce apoptosis of human retinal pigment epithelial cells. *Exp Eye Res* 1998;67:525-530

Rieger J, Ständer M, Löschmann PA, Heneka M, Dichgans J, Klockgether T, Weller M. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF- β , dexamethasone, and p53 gene transfer. *Oncogene* 1998;17:2323-2332

Hueber A, Durka S, Weller M. CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression. *FEBS Lett* 1998;432:155-157

Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, Von Deimling A, Dichgans J. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. *Int J Cancer* 1998;79:640-644

Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M. BCL-2 promotes migration and invasiveness of human glioma cells. *FEBS Lett* 1998;440:419-424

Roller A, Weller M. Antioxidants specifically inhibit cisplatin toxicity of human malignant glioma cells. *Anticancer Res* 1998;18:4493-4497

Wagenknecht B, Schulz JB, Gulbins E, Weller M. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. *Cell Death Differ* 1998;5:894-900

Streffer J, Schuster M, Zipp F, Weller M. Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy? *J Neuro-Oncol* 1998;40:233-235

1999

Rieger J, Ohgaki H, Kleihues P, Weller M. Human astrocytic brain tumors express APO2L/TRAIL. *Acta Neuropathol* 1999;97:1-4

Simons M, Beinroth S, Gleichmann M, Liston P, Korneluk RG, MacKenzie AE, Bähr M, Klockgether T, Robertson GS, Weller M, Schulz JB. Adenovirus-mediated gene transfer of IAPs delays apoptotic cell death in cerebellar granule neurons. *J Neurochem* 1999;72:292-301

Abele M, Weller M, Mescheriakov S, Bürk K, Dichgans J, Klockgether T. Immunoglobulin treatment in a case of cerebellar ataxia with autoantibodies to glutamic acid decarboxylase. *Neurology* 1999;52:857-859

Glaser T, Winter S, Groscurth P, Safayhi H, Sailer ER, Ammon HPT, Schabet M, Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug toxicity. *Br J Cancer* 1999;80:756-765

Pohl U, Wagenknecht B, Naumann U, Weller M. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. *Cell Physiol Biochem* 1999;9:29-37

Leonhardt M, Abele M, Klockgether T, Dichgans J, Weller M. Pathological yawning (chasm) associated with periodic leg movements in sleep (PLMS): cure by levodopa. *J Neurol* 1999;246:621-622

Rieger J, Durka S, Streffer J, Dichgans J, Weller M. Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. *Eur J Pharmacol* 1999;365:301-308

Münz C, Naumann U, Grimmel C, Rammensee HG, Weller M. TGF- β -independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells? *Eur J Immunol* 1999;29:1032-1040

Schmidt F, Schuster M, Streffer J, Schabet M, Weller M. Topotecan-based combination chemotherapy for human malignant glioma. *Anticancer Res* 1999;19:1217-1222

- Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. *J Pharmacol Exp Ther* 1999;289:1306-1312
- Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. *Oncogene* 1999;18:3936-3943
- Wüllner U, Kornhuber J, Weller M, Schulz JB, Löschmann PA, Riederer P, Klockgether T. Cell death and apoptosis regulating proteins in Parkinson's disease: a cautionary note. *Acta Neuropathol* 1999;97:408-412
- Wagenknecht B, Glaser T, Naumann U, Kügler S, Isenmann S, Bähr M, Korneluk R, Liston P, Weller M. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. *Cell Death Differ* 1999;6:370-376
- Deininger M, Weller M, Streffer J, Meyermann R. Patterns of cyclooxygenase-1 and -2 expression in human gliomas *in vivo*. *Acta Neuropathol* 1999;98:240-244
- Bartussek C, Naumann U, Weller M. Accumulation of p53 modulates the growth, clonogenicity and radiochemosensitivity of malignant glioma cells independently of their endogenous p53 status. *Exp Cell Res* 1999;253:432-439
- Borbé R, Rieger J, Weller M. The failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. *Cancer Chemother Pharmacol* 1999;44:217-227
- Eitel K, Wagenknecht B, Weller M. Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. *Cancer Lett* 1999;142:11-16
- Engel S, Isenmann S, Ständer M, Rieger J, Bähr M, Weller M. Inhibition of experimental rat glioma growth by decorin gene transfer does not involve enhanced microglial recruitment. *J Neuroimmunol* 1999;99:13-18
- Soldner F, Weller M, Haid S, Beinroth S, Miller SW, Wüllner U, Davis RE, Dichgans J, Klockgether T, Schulz JB. MPP+ inhibits proliferation of PC12 cells by a p21WAF1/Cip1-dependent pathway and induces cell death in cells lacking p21WAF1/Cip1. *Exp Cell Res* 1999;250:75-85
- Glaser T, Wagenknecht B, Groscurth P, Krammer PH, Weller M. Death ligand/receptor-independent caspase activation mediates drug-induced cell death in malignant glioma cells. *Oncogene* 1999;18:5044-5053
- Evert BO, Wüllner U, Schulz JB, Weller M, Groscurth P, Trottier Y, Brice A, Klockgether T. High-level expression of expanded full-length ataxin-3 causes cell death and formation of intranuclear inclusions in neuronal cells *in vitro*. *Hum Mol Genet* 1999;8:1169-1176
- Wagenknecht B, Hermisson M, Eitel K, Weller M. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. *Cell Physiol Biochem* 1999;9:117-125
- Deininger M, Weller M, Streffer J, Meyermann R. Antiapoptotic BCL-2 family protein expression increases in oligodendroglioma progression. *Cancer* 1999;86:1832-1839
- Wüllner U, Seyfried J, Groscurth P, Beinroth S, Winter S, Gleichmann M, Heneka M, Löschmann PA, Schulz JB, Weller M, Klockgether T. Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. *Brain Res* 1999;826:53-62
- Roller A, Bähr O, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. *Biochem Biophys Res Commun* 1999;259:600-605

Weller M, List U, Schabet M, Melms A, Dichgans J. Elevated CSF lactoferrin in superficial siderosis of the central nervous system. *J Neurol* 1999;246:943-945

Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R. Bcl-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. *J Neurol Neurosurg Psychiatry* 1999;67:763-768

Streffer J, Schuster M, Pohl U, Belka C, Dichgans J, Bamberg M, Weller M. Irradiation-induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions. *Anticancer Res* 1999;19:5265-5270

Pohl U, Wick W, Weissenberger J, Steinbach JP, Dichgans J, Aguzzi A, Weller M. Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. *Int J Oncol* 1999;15:829-834

Naumann U, Weit S, Rieger L, Meyermann R, Weller M. p27 modulates cell cycle progression and chemosensitivity in human malignant glioma. *Biochem Biophys Res Commun* 1999;261:890-896

Klöcker N, Kermer P, Gleichmann M, Weller M, Bähr M. Both the neuronal and inducible isoform contribute to upregulation of retinal NOS activity by BDNF. *J Neurosci* 1999;19:8517-8527

Lepple-Wienhues A, Belka C, Laun T, Jekle A, Walter B, Wieland U, Welz M, Heil L, Kun J, Busch G, Weller M, Bamberg M, Gulbins E, Lang F. Stimulation of CD95 (FAS) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. *Proc Natl Acad Sci USA* 1999;96:13975-13800

Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. *Biochem Biophys Res Commun* 1999;265:479-483

2000

Zipp F, Beyer M, Gelderblom H, Wernet D, Zschenderlein R, Weller M. No induction of apoptosis by IFN- β in human antigen-specific T cells. *Neurology* 2000;54:485-487

Rieger L, Rieger J, Winter S, Esser P, Dichgans J, Meyermann R, Weller M. Evidence for a constitutive, verapamil-sensitive, non-Pgp multidrug resistance phenotype that is unaltered by radiochemotherapy in vivo. *Acta Neuropathol* 2000;99:555-562

Herrlinger U, Klingel K, Meyermann R, Kandolf R, Kaiserling E, Kortmann RD, Melms A, Skalej M, Dichgans J, Weller M. Central nervous system Hodgkin's lymphoma without systemic manifestation: case report and review of the literature. *Acta Neuropathol* 2000;99:709-714

Nakamura M, Rieger J, Weller M, Kim J, Kleihues P, Ohgaki H. APO2L/TRAIL expression in human brain tumors. *Acta Neuropathol* 2000;99:1-6

Wüllner U, Weller M, Kornhuber J, Bornemann A, Schulz JB, Riederer P, Klockgether T. Altered expression of calcium- and apoptosis-regulating proteins in multiple system atrophy Purkinje cells. *Movement Disorders* 2000;15:269-275

Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R, Weller M. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. *Neurology* 2000;54:1357-1365

Roth W, Grimm C, Rieger L, Strik H, Takayama S, Krajewski S, Meyermann R, Reed JC, Weller M. Bag-1 and bcl-2 gene transfer in malignant glioma: modulation of cell cycle regulation and apoptosis. *Brain Pathol* 2000;10:223-234

Herrlinger U, Brugger W, Bamberg M, Küker W, Dichgans J, Weller M. PCV salvage chemotherapy for

recurrent primary CNS lymphoma. *Neurology* 2000;54:1707-1708

Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, Dichgans J, Weller M. A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. *J Neurol* 2000;247:297-302

Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary CNS lymphoma with long-term azathioprine therapy for myasthenia gravis? *Ann Neurol* 2000;47:682-683

Gleichmann M, Weller M, Schulz JB. Insulin-like growth factor (IGF)-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation. *Neurosci Lett* 2000;282:69-72

Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors β_1 (TGF- β_1) and TGF- β_2 promote glioma cell migration *via* up-regulation of $\alpha_v\beta_3$ integrin expression. *Biochem Biophys Res Commun* 2000;268:607-611

Hermisson M, Wagenknecht B, Wolburg H, Glaser T, Dichgans J, Weller M. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. *Oncogene* 2000;19:2338-2345

Küker W, Friese S, Vogel M, Schmidt F, Weller M. Incomplete resolution of basilar artery occlusion after intraarterial thrombolysis: abciximab and heparin prevent early rethrombosis. *Cerebrovasc Dis* 2000;10:484-486

Hermisson M, Weller M. Hyperthermia enhances the chemosensitivity of human malignant glioma cells. *Anticancer Res* 2000;20:1819-1824

Wendling U, Walczak H, Dörr J, Jacobi C, Weller M, Krammer PH, Zipp F. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. *Cell Death Differ* 2000;7:637-644

Winter S, Weller M. Poly(ADP-ribose)polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. *Eur J Pharmacol* 2000;398:177-183

Schmidt F, Wick W, Herrlinger U, Dichgans J, Weller M. Treosulfan chemotherapy for recurrent malignant glioma. *J Neuro-Oncol* 2000;49:231-234

Schmidt F, Groscurth P, Dichgans J, Weller M. Human malignant glioma cells are refractory to retinoic acid-mediated differentiation and sensitization to apoptosis. *Cell Physiol Biochem* 2000;10:159-168

Zipp F, Wendling U, Beyer M, Grieger U, Walczies S, Wagenknecht B, Haas J, Weller M. Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells. *J Neuroimmunol* 2000;110:214-222

Kirschnek S, Paris F, Weller M, Ferlinz K, Riehle A, Fuks Z, Kolesnick R, Gulbins E. CD95-mediated apoptosis *in vivo* involves acid sphingomyelinase. *J Biol Chem* 2000;275:27316-27323

Roth W, Wild-Bode C, Platten M, Grimm C, Melkonyan HS, Dichgans J, Weller M. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. *Oncogene* 2000;19:4210-4220

Grassmé H, Kirschnek S, Riethmüller J, Riehle A, von Kürthy G, Lang F, Weller M, Gulbins E. Host defense to *Pseudomonas aeruginosa* requires mammalian cell apoptosis via CD95/CD95 ligand. *Science* 2000;290:527-530

Wagenknecht B, Hermisson M, Groscurth P, Liston P, Krammer PH, Weller M. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. *J Neurochem* 2000;75:2288-2297

Winter S, Strik H, Rieger J, Beck J, Meyermann R, Weller M. Glutathione S-transferase and drug sensitivity in malignant glioma. *J Neurol Sci* 2000;179:115-121

Vietor M, Winter S, Groscurth P, Naumann U, Weller M. On the significance of telomerase activity in human malignant glioma cells. *Eur J Pharmacol* 2000;407:27-37

Strik H, Weller M, Frank B, Hermisson M, Deininger MH, Dichgans J, Meyermann R. Heat shock protein expression in human gliomas. *Anticancer Res* 2000;20:4457-4462

Eberhardt O, v. Coelln R, Kügler S, Lindenau J, Rathke-Hartlieb S, Gerhardt E, Haid S, Isenmann S, Gravel C, Srinivasan A, Bähr M, Weller M, Dichgans J, Schulz JB. Protection by synergistic effects of adenovirus-mediated XIAP and GDNF gene transfer in the MPTP model of Parkinson's disease. *J Neurosci* 2000;20:9126-9134

2001

Weller M, Streffer J, Wick W, Kortmann RD, Heiss E, Küker W, Meyermann R, Dichgans J, Bamberg M. Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma: a phase II study. *Cancer* 2001;91:423-427

Weber RG, Rieger J, Naumann U, Lichter P, Weller M. Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. *Int J Cancer* 2001;91:213-218

Küker W, Schmidt F, Friese S, Block F, Weller M. Unilateral thalamic oedema in internal cerebral venous thrombosis. *Cerebrovasc Dis* 2001;12:341-345

Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. *Acta Neuropathol* 2001;101:217-224

Isenmann S, Engel S, Kügler S, Gravel C, Weller M, Bähr M. Intravitreal adenoviral gene transfer evokes an immune response in the retina that is directed against the heterologous lacZ transgene product but does not limit transgene expression. *Brain Res* 2001;892:229-240

Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kanz L, Bamberg M, Dichgans J, Weller M. Primary CNS lymphoma 1991-1997: Outcome and late adverse effects after combined modality treatment. *Cancer* 2001;91:130-135

Schmidt F, Rieger J, Wischhusen J, Naumann U, Weller M. Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. *Eur J Pharmacol* 2001;412:21-25

Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, Weller M. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. *Cell Death Differ* 2001;8:403-410

Brötz D, Weller M, Küker W, Dichgans J, Götz A. Mechanische physiotherapeutische Diagnostik und Therapie bei Patienten mit lumbalen Bandscheibenvorfällen. *Aktuel Neurol* 2001;28:74-81

Glaser T, Castro M, Lowenstein P, Weller M. Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells. *Gene Therapy* 2001;8:469-476

Von Coelln R, Kügler S, Bähr M, Weller M, Dichgans J, Schulz JB. Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. *J Neurochem* 2001;77:263-273

Gerhardt E, Kügler S, Leist M, Beier C, Berliocchi L, Volbracht C, Weller M, Bähr M, Nicotera P, Schulz JB. Cascade of caspase activation in potassium-deprived cerebellar granule neurons: targets for treatment with peptide and protein inhibitors of apoptosis. *Mol Cell Neurosci* 2001;17:717-731

- Streffer J, Bitzer M, Schabet M, Dichgans J, Weller M. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. *Neurology* 2001;56:1219-1221
- Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bähr M, Ohgaki H, Ashkenazi A, Weller M. The soluble decoy receptor-3 is expressed by malignant glioma and suppresses CD95 ligand-induced apoptosis and chemotaxis. *Cancer Res* 2001;61:2759-2765
- Glaser T, Weller M. Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. *Biochem Biophys Res Commun* 2001;281:322-327
- Wild-Bode C, Weller M, Rimmer A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. *Cancer Res* 2001;61:2744-2750
- Wagenknecht B, Roth W, Gulbins E, Wolburg H, Weller M. C2-ceramide signalling in glioma cells: synergistic enhancement of CD95-mediated, caspase dependent apoptosis. *Cell Death Differ* 2001;8:595-602
- Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits TGF- β release and reduces migration and invasiveness of human malignant glioma cells. *Int J Cancer* 2001;93:53-61
- Bähr O, Wick W, Weller M. Modulation of MDR/MRP by wild-type and mutant p53 (letter). *J Clin Invest* 2001;107:643-645
- Wick W, Grimmel C, Wild-Bode C, Platten M, Arpin M, Weller M. Ezrin-dependent promotion of glioma cell clonogenicity, motility and invasion mediated by BCL-2 and TGF- β ₂. *J Neurosci* 2001;21:3360-3368
- Bühning U, Herrlinger U, Krings T, Thiex R, Weller M, Küker W. MRI features of primary central nervous system lymphomas (PCNSL) at presentation. *Neurology* 2001;57:393-396
- Glaser T, Wagenknecht B, Weller M. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells. *Oncogene* 2001;20:4757-4767
- Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration and invasion. *J Neurosurg* 2001;94:978-984
- Leitlein J, Aulwurm S, Waltereit R, Naumann U, Wagenknecht B, Garten W, Weller M, Platten M. Processing of immunosuppressive pro-TGF- β _{1,2} by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. *J Immunol* 2001;166:7238-7243
- Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. *Oncogene* 2001;20:4128-4137
- Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M, Weller M. Chimeric tumor suppressor 1 (CTS1), a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. *Cancer Res* 2001;61:5833-5842
- Xia XG, Harding T, Weller M, Bienemann A, Uney JB, Schulz JB. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. *Proc Natl Acad Sci USA* 2001;98:10433-10438
- Naumann U, Weit S, Wischhusen J, Weller M. Diva/boo is a negative regulator of cell death in human glioma cells. *FEBS Lett* 2001;505:23-26

Wick W, Platten M, Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF- β . *J Neuro-Oncol* 2001;53:177-185

Platten M, Wick W, Wischhusen J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (traniLAST) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon- γ (IFN- γ). *Br J Pharmacol* 2001;134:1279-1284

Grassmé H, Kirschnek S, Riethmueller J, Riehle A, von Kürthy G, Lang F, Weller M, Gulbins E. Role of apoptosis in *Pseudomonas aeruginosa* pneumonia. *Science* 2001;294:1783a (Reply)

Rimner A, Wischhusen J, Naumann U, Gleichmann M, Steinbach JP, Weller M. Identification by suppression subtractive hybridization of p21 as a radio-inducible gene in human glioma cells. *Anticancer Res* 2001;21:3505-3508

2002

Steinbach JP, Supra P, Huang HJS, Cavenee WK, Weller M. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. *Brain Pathol* 2002;12:12-20

Herrlinger U, Weller M, Küker W. Primary CNS lymphoma of the spinal cord: clinical manifestation may precede MRI detectability. *Neuroradiology* 2002;44:239-244

Hermisson M, Klein R, Schmidt F, Weller M, Küker W. Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. *Acta Neurol Scand* 2002;105:450-453

Gleichmann M, Buchheim G, El-Bizri H, Yokota Y, Klockgether T, Kügler S, Bähr M, Weller M, Schulz JB. Identification of inhibitor-of-differentiation 2 as a modulator of neuronal apoptosis. *J Neurochem* 2002;80:755-762

Von Pfeil A, Hakenjos L, Herskind C, Dittmann KH, Weller M, Rodemann HP. Irradiated homozygous TGF β 1-knockout fibroblasts show enhanced clonogenic survival as compared to TGF β 1-wild-type fibroblasts. *Int J Radiat Biol* 2002;78:331-339

Herrlinger U, Schabet M, Brugger W, Kortmann RD, Küker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benöhr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M, Weller M, for the Neuro-Oncology Working Group (NOA) of the German Cancer Society. German cancer society neuro-oncology group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. *Ann Neurol* 2002;51:247-252

Hueber A, Welsandt G, Jordan JF, Mietz H, Weller M, Krieglstein GK, Esser PJ. Characterization of CD95 ligand (CD95L)-induced apoptosis in human Tenon fibroblasts. *Exp Eye Res* 2002;75:1-8

Streffer JR, Rimner A, Rieger J, Naumann U, Rodemann HP, Weller M. Bcl-2 family protein expression modulates radiosensitivity in human glioma cells. *J Neuro-Oncol* 2002;56:43-49

Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. *Cancer Res* 2002;62:1915-1919

Herrlinger U, Küker W, Dichgans J, Weller M. First-line therapy with temozolomide induces regression of primary CNS lymphoma. *Neurology* 2002;58:1573-1574

Wiendl H, Mitsdörffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, Weiss EH, Melms A, Weller M. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. *J Immunol* 2002;168:4772-4780

Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H,

Aguzzi A, Rammensee HG, Weller M. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. *Cancer Res* 2002;62:2592-2599

Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M, Kleihues P, Ohgaki H. Methylation of the p73 gene in gliomas. *Acta Neuropathol* 2002;104:357-362

Reichert M, Steinbach J, Supra P, Weller M. Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis. A new look at the efficacy of nitrosoureas. *Cancer* 2002;95:1113-1119

Wick W, Hermisson M, Küker WM, Kortmann RD, Duffner F, Dichgans J, Bamberg M, Weller M. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma. A phase II study. *J Neuro-Oncol* 2002;59:151-155

Waltereit R, Küker W, Jürgens S, Weller M, Dichgans J, Wiendl H. Acute transverse myelitis associated with coxiella burnetii infection. *J Neurol* 2002;249:1459-1461

Wick W, Stock J, Seyfried J, Baumgart J, Wüllner U, Weller M. CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by a glutathione depleting agent, BSO, in malignant glioma cells in vitro and in vivo. *Int J Oncol* 2002;21:213-200

Müller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. *Am J Pathol* 2002;161:313-319

Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. *J Neurol* 2002;249:1409-1412

Herrlinger U, Felsberg J, Küker W, Bornemann A, Plasswilm L, Knobbe CB, Strik H, Wick W, Meyermann R, Dichgans J, Bamberg M, Reifenberger G, Weller M. Gliomatosis cerebri. Molecular pathology and clinical course. *Ann Neurol* 2002;52:390-399

Hipp MS, Urbich V, Mayer P, Wischhusen J, Weller M, Kracht M, Spyridopoulos I. Proteasome inhibition leads to NF- κ B independent interleukin-8 transactivation in human endothelial cells through induction of AP-1. *Eur J Immunol* 2002;32:2208-2217

Wick A, Wick W, Waltenberger J, Weller M, Dichgans J, Schulz JB. Hypoxic neuroprotection requires sequential activation of vascular endothelial growth factor receptor and Akt. *J Neurosci* 2002;22:6401-6407

Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for TRAIL/Apo2L- or anticancer drug-induced apoptosis and induce regression of human glioma xenografts. *Nat Med* 2002;8:808-815

Küker W, Herrlinger U, Grönwaller E, Rohrbach JM, Weller M. Ocular manifestation of PCNSL: what can be expected from imaging? *J Neurol* 2002;249:1713-1716

Nylandsted J, Wick W, Hirt UA, Brand K, Rohde M, Leist M, Weller M, Jäättelä M. Eradication of glioblastoma and breast and colon carcinoma xenografts by Hsp70 depletion. *Cancer Res* 2002;62:7139-7142

Waltereit R, Weller M. The role of caspase 9 and 9-short (9S) in death ligand- and drug-induced apoptosis in human astrocytoma cells. *Mol Brain Res* 2002;106:42-49

2003

Wiendl H, Mitsdörffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmüller H, Hohlfeld R, Melms A, Weller M. The nonclassical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. *Brain* 2003;126:176-185

- Naumann U, Waltereit R, Schulz JB, Weller M. Adenoviral (full length) Apo2L/TRAIL gene therapy is an ineffective treatment strategy for malignant glioma. *J Neuro-Oncol* 2003;61:7-15
- Wiendl H, Mitsdörffer M, Schneider D, Melms A, Lochmüller H, Hohlfeld R, Weller M. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible costimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. *Brain* 2003;126:1026-1035
- Rieger J, Wick W, Weller M. Human malignant glioma cell lines express semaphorins and their receptors, neuropilins and plexins. *Glia* 2003;42:379-389
- Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E. Host defense against *P. aeruginosa* requires ceramide-rich membrane rafts. *Nat Med* 2003;9:322-330
- Wiendl H, Feiden W, Scherieble H, Renz T, Dichgans J, Weller M. A 41 year old woman with a solitary lesion in the liver. *Brain Pathol* 2003;13:421-423
- Brötz D, Küker W, Maschke E, Wick W, Dichgans J, Weller M. A prospective trial of mechanical physiotherapy for lumbar disk prolapse. *J Neurol* 2003;250:746-749
- Hueber A, Weller M, Welsandt G, Kociok N, Kirchhof B, Esser P. Daunorubicin induces apoptosis in retinal pigment epithelial cells. Modulation by CD95L. *Invest Ophthalmol Vis Sci* 2003;44:2851-2857
- Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M. Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. *Cell Death Differ* 2003;10:823-832
- Wiendl H, Neuhaus O, Mehling M, Wintterle S, Schreiner B, Mitsdörffer M, Wienhold W, Weissert R, Wessels J, Hartung HP, Weller M, Tolosa E, Melms A. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. *J Neuroimmunol* 2003;140:177-187
- Hermisson M, Weller M. NF- κ B-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signalling pathways in human malignant glioma cells. *Cell Death Differ* 2003;10:1078-1089
- Platten M, Kretz A, Naumann U, Aulwurm S, Isenmann S, Weller M. MCP-1 increases macrophage infiltration and aggressiveness of murine gliomas. *Ann Neurol* 2003;54:388-392
- Wiendl H, Mitsdörffer M, Schneider D, Chen L, Lochmüller H, Melms A, Weller M. Human muscle cells express the negative regulatory B7-related molecule B7-H1 (PD-L1): a mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies? *FASEB J* 2003;17:1892-1894
- Schreiner B, Wischhusen J, Mitsdörffer M, Schneider D, Bornemann A, Melms A, Tolosa E, Weller M, Wiendl H. Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. *Glia* 2003;44:296-301
- Platten M, Eitel K, Wischhusen J, Dichgans J, Weller M. Involvement of protein kinase Cd and extracellular signal-regulated kinase-1/2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). *Biochem Pharmacol* 2003;66:1263-1270
- Naumann U, Schmidt F, Wick W, Frank B, Weit S, Gillissen B, Daniel P, Weller M. Adenoviral natural born killer (NBK) gene therapy of malignant glioma. *Hum Gene Therapy* 2003;14:1235-1246
- Neuro-Oncology Working Group (NOA) of the German Cancer Society. Neuro-Oncology Working Group (NOA)-01 trial of ACNU/VM26 *versus* ACNU/Ara-C chemotherapy in addition to involved-field

radiotherapy in the first-line treatment of malignant glioma. *J Clin Oncol* 2003;21:3276-3284 (Corresponding author)

Bähr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. *Brain Pathol* 2003;13:482-494

Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and expression in glioblastomas. *Acta Neuropathol* 2003;106:479-485

Herrlinger U, Schwärzler F, Beck R, Küker W, Hebart H, Kanz L, Dichgans J, Weller M. Progressive multifocal leukoencephalopathy. Cidofovir therapy in three patients with underlying haematological disease. *J Neurol* 2003;250:612-614

Wintterle S, Schreiner B, Mitsdörffer M, Schneider D, Chen L, Meyermann R, Weller M, Wiendl H. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. *Cancer Res* 2003;63:7462-7467

Meuth SG, Budde T, Duyar H, Landgraf P, Broicher T, Elbs M, Brock R, Weller M, Weissert R, Wiendl H. Modulation of neuronal activity by the endogenous pentapeptide QYNAD. *Eur J Neurosci* 2003;18:2697-2706

Weissert R, Wiendl H, Pfrommer H, Storch MK, Schreiner B, Barth S, Seifert T, Melms A, Dichgans J, Weller M. Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. *J Neuroimmunol* 2003;144:28-37

Friese MA, Platten M, Lutz SZ, Naumann U, Aulwurm S, Bischof F, Bühring HJ, Dichgans J, Rammensee HG, Steinle A, Weller M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. *Cancer Res* 2003;63:8996-9006

Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent cell death. *Oncogene* 2003;22:8233-8245

2004

Naumann U, Wick W, Beschoner R, Meyermann R, Weller M. Expression and functional activity of osteoprotegerin in human malignant gliomas. *Acta Neuropathol* 2004;107:17-22

Herrlinger U, Aulwurm S, Strik H, Weit S, Naumann U, Weller M. MIP-1alpha antagonizes the effect of a GM-CSF and IL-4-enhanced subcutaneous vaccine in a mouse glioma model. *J Neuro-Oncol* 2004;66:147-154

Steinbach JP, Klumpp A, Wolburg H, Weller M. Inhibition of epidermal growth factor receptor signalling protects human malignant glioma cells from hypoxia-induced cell death. *Cancer Res* 2004;64:1575-1578

Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. *Neurology* 2004;62:2113-2115

Küker W, Weller M, Klose U, Krapf H, Dichgans J, Nägele T. Diffusion-weighted MRI of spinal cord infarction: high resolution imaging and time course of diffusion abnormality. *J Neurol* 2004;251:818-824

Wick W, Wick A, Küker W, Dichgans J, Weller M. Intracranial metastatic esthesioneuroblastoma responsive to temozolomide. *J Neuro-Oncol* 2004;70:73-75

Eberhardt O, Küker W, Dichgans J, Weller M. HSV-2 sacral radiculitis (Elsberg syndrome). *Neurology* 2004;63:758-759

Wischhusen J, Melino G, Weller M. p53 and its family members – reporter genes may not see the

difference. *Cell Death Differ* 2004;11:1150-1152

Herrlinger U, Wiendl H, Renninger M, Förschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. *Br J Cancer* 2004;91:219-224

Herrlinger U, Förschler H, Küker W, Meyermann R, Bamberg M, Dichgans J, Weller M. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. *J Neurol Sci* 2004;223:167-178

Steinbach J, Eisenmann C, Klumpp A, Weller M. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. *Biochem Biophys Res Commun* 2004;321:524-530

Schreiner B, Mitsdörffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Interferon- β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T cell activation: relevance for the immune modulatory effect in multiple sclerosis. *J Neuroimmunol* 2004;155:172-182

Wick A, Wick W, Hirrlinger J, Gerhardt E, Dringen R, Dichgans J, Weller M, Schulz JB. Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. *J Neurochem* 2004;91:1067-1074

Naumann U, Wischhusen J, Weit S, Wolburg H, Massing U, Weller M. Alkylphosphocholine-induced glioma cell death is BCL-X_L-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation. *Cell Death Differ* 2004;11:1326-1341

Wick W, Wild-Bode C, Frank B, Weller M. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. *J Neurochem* 2004;91:1275-1283

Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, Weller M. RNA interference targeting TGF- $\beta_{1,2}$ enhances NKG2D-mediated anti-glioma immune response, inhibits glioma cell migration and invasiveness and abrogates tumorigenicity *in vivo*. *Cancer Res* 2004;64:7596-7603

Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a novel TGF- β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells *in vitro* and *in vivo*. *Cancer Res* 2004;64:7954-7961

Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Löwenstein PR. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. *Cancer Gene Ther* 2004;11:721-732

Herrlinger U, Rieger J, Steinbach JP, Nägele T, Dichgans J, Weller M. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. *J Neuro-Oncol* 2005;71:295-299

Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD, Meyermann R, Schabet M, Bamberg M, Dichgans J, Bogdahn U, Weller M. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. *J Neurol* 2005;252:291-299

Duffner F, Ritz R, Freudenstein D, Weller M, Dietz K, Wessels J. Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX. *J Neuro-Oncol* 2005;71:107-111

Küker W, Nägele T, Korfel A, Heckl S, Thiel E, Bamberg M, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. *J Neuro-Oncol*

2005;72:169-177

Mitsdörffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, Weller M, Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T-cell activation and is up-regulated by interferon- β in vitro and in vivo: rationale for the therapy of multiple sclerosis. *J Neuroimmunol* 2005;159:155-164

Jahnke K, Korfel A, Martus M, Weller M, Herrlinger U, Schmittl A, Fischer L, Thiel E, on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. *Ann Oncol* 2005;16:445-449

Steinbach JP, Wolburg H, Klumpp A, Weller M. Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death. *J Neurochem* 2005;92:1340-1349

Jahnke K, Thiel E, Schilling A, Herrlinger U, Weller M, Coupland SE, Krümpelmann U, Stein H, Korfel A. Low-grade primary central nervous system lymphoma in immunocompetent patients. *Br J Hematol* 2005;128:616-624

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Cairncross JG, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin S, Gorlia T, Allgeier A, Lacombe D, Eisenhauer E, Mirimanoff RO, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. *N Engl J Med* 2005;352:987-996

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason WP, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross G, Janzer R, Stupp R. MGMT gene silencing and response to temozolomide in glioblastoma. *N Engl J Med* 2005;352:997-1003

Uhl M, Weiler M, Wick W, Jacobs AH, Weller M, Herrlinger U. Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. *Biochem Biophys Res Commun* 2005;328:125-129

Wischhusen J, Schneider D, Mittelbronn M, Meyermann R, Engelmann H, Jung G, Wiendl H, Weller M. Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. *J Neuroimmunol* 2005;162:28-42

Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, Lüders M, Tränkle C, Wick W, Weller M, Fahlbusch R, Blümcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. *J Neurochem* 2005;93:992-999

Herrlinger U, Hebart H, Kanz L, Dichgans J, Weller M. Relapse of primary CNS lymphoma after more than 10 years in complete remission. *J Neurol* 2005;252:1409-1410

Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. *J Clin Oncol* 2005;23:4235-4236

Wischhusen J, Friese M, Mittelbronn M, Meyermann R, Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. *J Neuropathol Exp Neurol* 2005;64:523-528

Herrlinger U, Küker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M, for the Neuro-Oncology Working Group of the German Cancer Society. NOA-03 multicenter trial of high-dose methotrexate in primary CNS lymphoma: final report. *Ann Neurol* 2005;57:843-847

Amatya VJ, Naumann U, Weller M, Ohgaki H. *TP53* promoter methylation in human gliomas. *Acta Neuropathol* 2005;110:178-184

Küker W, Nägele T, Thiel E, Weller M, Herrlinger U. Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. *Neurology* 2005;65:1129-1131

Beier CP, Wischhusen J, Gleichmann M, Gerhardt E, Pekanovic A, Krüger A, Taylor V, Suter U, Krammer PH, Endres M, Weller M, Schulz JB. FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. *J Neurosci* 2005;25:6765-6774

Tabatabai G, Bähr O, Möhle R, Eyüpoglu IY, Böhmler AM, Wischhusen J, Rieger J, Blümcke I, Weller M, Wick W. Lessons from the bone marrow: how malignant glioma cells attract adult hematopoietic progenitor cells. *Brain* 2005;128:2200-2211

Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brück W, Meyermann R, Bar-Or A, Kieseier BC, Weller M. Expression of the immune tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. *Brain* 2005;128:2689-2704

Grosse-Hovest L, Wick W, Minoia R, Weller M, Rammensee HG, Brem G, Jung G. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. *Int J Cancer* 2005;117:1060-1064

Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, Weller M. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? *Onkologie* 2005;28:391-396

Danielyan L, Mueller L, Proksch B, Kabisch D, Weller M, Wiesinger H, Bunitian GH, Gleiter CH. Similar protective effects of BQ-123 and erythropoietin on survival of neural cells and generation of neurons upon hypoxic injury. *Eur J Cell Biol* 2005;84:907-913

Ritz R, Müller M, Weller M, Dietz K, Kuci S, Roser F, Tatagiba M. Hypericin: a promising fluorescence marker for differentiating between glioblastoma and neurons in vitro. *Int J Oncol* 2005;27:1543-1549

2006

Naumann U, Huang H, Wolburg H, Wischhusen J, Weit S, Ohgaki H, Weller M. PCTAIRE3: a putative mediator of growth arrest and death induced by CTS-1, a dominant-positive p53-derived synthetic tumor suppressor, in human malignant glioma cells. *Cancer Gene Ther* 2006;13:469-478

Waltereit R, Welzl H, Dichgans J, Lipp HP, Schmidt WJ, Weller M. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. *J Neurochem* 2006;96:407-413

Steinbach JP, Blaicher HP, Herrlinger U, Wick W, Nägele T, Meyermann R, Tatagiba M, Bamberg M, Dichgans J, Karnath HO, Weller M. Surviving glioblastoma for more than 5 years: the patients' perspective. *Neurology* 2006;66:239-242

Eisele G, Wischhusen J, Mittelbronn M, Meyermann R, Waldhauer I, Steinle A, Weller M, Friese MA. TGF- β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. *Brain* 2006;129:2416-2425

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M. O⁶-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. *J Neurochem* 2006;96:766-776

Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M. PCV chemotherapy for recurrent glioblastoma. *Neurology* 2006;66:587-589

Weiler M, Bähr O, Hohlweg U, Naumann U, Rieger J, Huang H, Tabatabai G, Krell HW, Ohgaki H, Weller M, Wick W. BCL-x(L): time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. *Cell Death Differ* 2006;13:1156-1169

Fischer L, Jahnke K, Martus P, Weller M, Thiel E, Korfel A. The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. *Haematologica* 2006;91:429-430

Aulwurm S, Wischhusen J, Friese M, Borst B, Weller M. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting anti-glioma immunity in vivo. *Int J Cancer* 2006;118:1728-1735

Roth P, Aulwurm S, Gekel I, Beier D, Sperry RG, Mittelbronn M, Meyermann R, Beaman KD, Weller M, Wischhusen J. Regeneration and tolerance factor (RTF): a novel mediator of glioblastoma-associated immunosuppression. *Cancer Res* 2006;66:3852-3858

Ernemann U, Rieger J, Tatagiba M, Weller M. An MRI view of a ruptured dermoid cyst. *Neurology* 2006;66:270

Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A, on behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. *J Neuro-Oncol* 2006;80:159-165

Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann R, Tan TC, Sommer C, Bamberg M, Reifenberger R, Weller M. UKT-03 phase II trial of CCNU plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma. *J Clin Oncol* 2006;24:4412-4417

Tabatabai G, Frank B, Möhle R, Weller M, Wick W. Irradiation and hypoxia promote homing of hematopoietic progenitor cells towards gliomas by TGF- β -dependent HIF-1 α -mediated induction of CXCL12. *Brain* 2006;129:2426-2435

Grassme H, Jin J, Wilker B, von Kürthy G, Wick W, Weller M, Möröy T, Gulbins E. Regulation of pulmonary *Pseudomonas aeruginosa* infection by the transcriptional repressor Gfi1. *Cell Microbiol* 2006;8:1096-1105

Eberhardt O, Nägele T, Raygrotzki S, Weller M, Ernemann U. Stenting of vertebrobasilar arteries in symptomatic atherosclerotic disease and acute occlusion: case series and review of the literature. *J Vasc Surg* 2006;43:1145-1154

Scheel B, Aulwurm S, Probst J, Hoerr I, Rammensee HG, Weller M, Pascolo S. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. *Eur J Immunol* 2006;36:2807-2816

2007

Burghardt I, Tritschler F, Opitz CA, Frank F, Weller M, Wick W. Pirfenidone inhibits TGF- β expression in malignant glioma cells. *Biochem Biophys Res Commun* 2007;354:542-547

Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM, Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O⁶-methylguanine. *Oncogene* 2007;26:186-197

Mittelbronn M, Kröber SM, Wersbe A, Weller M, Hewer W, Meyermann R, Kaiserling E, Beschoner R. A 63-year-old man with dementia, ataxia and VI nerve palsy. *Brain Pathol* 2007;17:466-467

Wiendl H, Kieseier BC, Weissert R, Mylius HA, Pichlmeier U, Hartung HP, Melms A, Küker W, Weller M. Treatment of active secondary progressive multiple sclerosis with treosulfan. *J Neurol* 2007;254:884-889

Mittelbronn M, Capper D, Bunz B, Dietz K, Goepfert B, Ajaaj R, Tabatabai T, Stubenvoll F, Schlaszus H, Merseburger AS, Becker R, Freudenstein D, Wick W, Weller M, Meyermann R, Simon P. De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. *Neuropathol Appl Neurobiol* 2007;33:299-307

Tabatabai G, Frank B, Wick A, Lemke D, Von Kürthy G, Obermüller U, Heckl S, Christ G, Weller M, Wick W. Synergistic antiglioma activity of radiotherapy and enzastaurin. *Ann Neurol* 2007;61:153-156

Warth A, Simon P, Capper D, Goepfert B, Tabatabai G, Herzog H, Dietz K, Stubenvoll F, Ajaaj R, Becker R, Weller M, Meyermann R, Wolburg H, Mittelbronn M. Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. *J Neurosci Res* 2007;85:1336-1346

Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH. Inhibiting TGF- β signaling restores immune surveillance in the SMA-560 glioma model. *Neuro-Oncology* 2007;9:259-270

Mittelbronn M, Schittenhelm J, Lemke D, Ritz R, Nägele T, Weller M, Meyermann R, Beschorner R. Low grade ganglioglioma rapidly progressing to a WHO grade IV tumor showing malignant transformation in both astroglial and neuronal cell components. *Neuropathology* 2007;27:463-467

Naumann U, Bähr O, Wolburg W, Altenberend S, Wick W, Liston P, Ashkenazi A, Weller M. Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. *Gene Therapy* 2007;14:147-161 (Corrigendum 2007;14:1434-1437)

Rieger J, Frank B, Weller M, Wick W. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand. *Cell Physiol Biochem* 2007;20:23-34

Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP. Radicular and non-radicular back pain in Parkinson's disease: a controlled study. *Movement Disorders* 2007;22:853-856

Kita D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. *Acta Neuropathol* 2007;113:295-302

Grammatikos G, Teichgräber V, Carpinteiro A, Trarbach T, Weller M, Hengge UR, Gulbins E. Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. *Antioxid Redox Sign* 2007;9:1449-1456

Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and tolerability of temozolomide in an one week on/one week off regimen in patients with recurrent glioma. *J Clin Oncol* 2007;25:3357-3361

Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? *Acta Neuropathol* 2007;114:111-119

Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. *Cancer Res* 2007;67:3540-3544

Mauer M, Stupp R, Taphoorn MJB, Coens C, Osoba D, Marosi C, Wong R, De Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, Van den Bent MJ, Weller M, Bottomley A. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an EORTC BTG, ROG, and NCIC international randomized phase III study. *Br J Cancer* 2007;97:302-307

Mittelbronn M, Simon P, Löffler C, Capper D, Bunz B, Harter P, Schlaszus H, Schleich A, Tabatabai G, Goepfert B, Meyermann R, Weller M, Wischhusen J. Elevated HLA-E levels in human glioblastomas but

not in grade I to III astrocytomas correlate with infiltrating CD8⁺ cells. *J Neuroimmunol* 2007;189:50-58

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G, for the German Glioma Network. Long-term survival with glioblastoma. *Brain* 2007;130:2596-2606

Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Löffler M, Pietsch P, von Deimling A, for the German Glioma Network. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? *Clin Cancer Res* 2007;13:6933-6937

2008

Brötz D, Hahn U, Maschke E, Wick W, Küker W, Weller M. Lumbar disk prolapse: response to mechanical physiotherapy in the absence of changes in magnetic resonance imaging. Report of 11 cases. *Neurorehabilitation* 2008;23:289-294

Gorlia T, Van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Denis Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. *Lancet Oncol* 2008;9:29-38

Roth P, Happold C, Eisele G, Nägele T, Weller M, Luft AR. A series of patients with subpial hemorrhage: clinical manifestation, neuroradiological presentation and therapeutic implications. *J Neurol* 2008;255:1018-1022

Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, DasMahapatra B, Weller M. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. *Cell Death Differ* 2008;15:718-729

Schmidt F, Knobbe CB, Frank B, Wolburg H, Weller M. The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. *Oncol Rep* 2008;19:1061-1066

Schittenhelm J, Reifenberger G, Ritz R, Nägele T, Weller M, Pantazis G, Capper D, Beschorner R, Meyermann R, Mittelbronn M. Primary anaplastic ganglioglioma with a small-cell glioblastoma component. *Clin Neuropathol* 2008;27:91-95

Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Hönig A, Häusler S, Voigt H, Becker JC, Leng L, Steinle A, Weller M, Bucala R, Dietl J, Wischhusen J. Macrophage migration inhibitory factor (MIF) contributes to the immune escape of ovarian cancer by down-regulating NKG2D. *J Immunol* 2008;180:7338-7348

Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, Van Heeckeren AM, Barr ML, Von Kürthy G, Schmid KW, Weller M, Tümmeler B, Lang F, Grassme H, Döring G, Gulbins E. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. *Nat Med* 2008;14:382-391

Wick W, Stupp R, Beule AC, Bromberg J, Wick A, Ernemann U, Platten M, Marosi C, Mason WP, van den Bent M, Weller M, Rorden C, Karnath HO, on behalf of the European Organisation for Research and Treatment of Cancer and the National Cancer Institute of Canada Clinical Trials Group. A novel tool to analyse MRI recurrence patterns in glioblastoma. *Neuro-Oncology* 2008;10:1019-1024

Naumann U, Maass P, Gleske Ak, Aulwurm S, Weller M, Eisele G. Glioma gene therapy with soluble transforming growth factor- β receptors II and III. *Int J Oncol* 2008;33:759-765

Acioly MA, Carvalho CH, Pinheiro-Franco JL, Schittenhelm J, Ernemann U, Weller M, Honegger J. Unusual presentation of central nervous system metastases: mechanisms of spread and radiological findings. *Arq Neuropsiquiatr* 2008;66:755-757

Glas M, Rasch K, Wiewrodt D, Weller M, Herrlinger U. Procarbazine and CCNU (PC) as initial treatment in gliomatosis cerebri. *Oncology* 2008;75:182-185

Waerzeggers Y, Klein M, Miletic H, Himmelreich U, Li H, Herrlinger U, Hoehn M, Coenen HH, Weller M, Winkeler A, Jacobs AH. Multimodal imaging of neural progenitor cell fate in rodents. *Mol Imaging* 2008;7:77-91

Strelau J, Schmeer C, Peterziel H, Paech T, Herold-Mende C, Steiner H, Weller M, Unsicker U. Expression and putative functions of GDF-15, a member of the TGF- β superfamily, in human glioma and glioblastoma cell lines. *Cancer Lett* 2008;270:30-39

Fischer L, Martus P, Weller M, Klasen HK, Rhoden B, Röth A, Storek B, Hummel M, Nägele T, Thiel E, Korfel A. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. *Neurology* 2008;71:1102-1108

Tabatabai G, Herrmann C, von Kürthy G, Mittelbronn M, Grau S, Frank B, Möhle R, Weller M, Wick W. VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult hematopoietic progenitor cells. *Brain* 2008;131:2579-2595

Kurzwelly D, Müller CA, Korfel A, Thiel E, Linnebank M, Weller M, Herrlinger U. Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients. *J Neuro-Oncol* 2008;90:53-55

Rieger J, Lemke D, Maurer G, Weiler M, Frank B, Tabatabai G, Weller M, Wick W. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-X_L. *J Neurochem* 2008;106:2436-2448

Happold C, Ernemann U, Roth P, Wick W, Weller M, Schmidt F. Anticoagulation for radiation-induced neurotoxicity revisited. *J Neuro-Oncol* 2008;90:357-362

Tabatabai G, Schöber W, Ernemann U, Weller M, Krüger R. Vertebral artery dissection presenting with ipsilateral acute C5 and C6 sensorimotor radiculopathy: a case report. *Cases Journal* 2008;1:139

2009

Maurer GD, Tritschler I, Adams A, Tabatabai G, Wick W, Stupp R, Weller M. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide *in vitro*. *Neuro-Oncology* 2009;11:747-756

Hofer S, Kollias S, Weller M. Evolution of glioblastoma. *Acta Oncol* 2009;48:630-631

Roth T, Sokolov AN, Messias A, Roth P, Weller M, Trauzettel-Klosinski S. Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. *Neurology* 2009;72:324-331

Schittenhelm J, Beschorner R, Simon P, Tabatabai G, Herrmann C, Schlaszus H, Capper D, Weller M, Meyermann R, Mittelbronn M. Diagnostic value of WT1 in neuroepithelial tumours. *Neuropathol Appl Neurobiol* 2009;35:69-81

Mittelbronn M, Harter P, Warth A, Lupescu A, Schilbach K, Vollmann H, Capper D, Goepfert B, Frei K, Bertalanffy H, Weller M, Meyermann R, Lang F, Simon P. EGR-1 is regulated by N-methyl-D-aspartate receptor stimulation and associated with patient survival in human high grade astrocytomas. *Brain Pathol* 2009;19:195-204

Happold C, Roth P, Wick W, Steinbach JP, Linnebank M, Weller M, Eisele G. ACNU-based chemotherapy for recurrent glioma in the temozolomide era. *J Neuro-Oncol* 2009;92:45-48

Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P. Rechallenge with temozolomide in patients with recurrent gliomas. *J Neurol* 2009;256:734-741

Glas M, Hoppold C, Rieger J, Wiewrodt D, Bähr O, Steinbach PJ, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. *J Clin Oncol* 2009;27:1257-1261

Tritschler I, Gramatzki D, Capper D, Mittelbronn M, Meyermann R, Saharinen J, Wick W, Keski-Oja J, Weller M. Modulation of TGF- β activity by latent TGF- β -binding protein 1 in human malignant glioma cells. *Int J Cancer* 2009;125:530-540

Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP. Antagonism of mTOR selectively mediates metabolic effects of EGFR inhibition and protects human malignant glioma cells from hypoxia-induced cell death. *Brain* 2009;132:1509-1522

Opitz CA, Litzenger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon- β and protein kinase R. *Stem Cells* 2009;27:909-919

Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz M, Weller M, Tritschler I. Aryl hydrocarbon receptor inhibition down-regulates the TGF- β /smad pathway in human glioblastoma cells. *Oncogene* 2009;28:2593-2605

Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 2009;10:459-466

Semmler A, Bao X, Cao G, Köhler W, Weller M, Aubourg P, Linnebank M. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. *J Neurol* 2009;256:1277-1280

Bähr O, Herrlinger U, Weller M, Steinbach JP. Very late relapses in glioblastoma long-term survivors. *J Neurol* 2009;256:1756-1758

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler OD, Reifenberger G, von Deimling A, Loeffler M, for the German Glioma Network. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translational study of the German Glioma Network. *J Clin Oncol* 2009;27:5743-5750

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken J, Wesseling P, Reifenberger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations in astrocytoma, oligodendroglioma and mixed oligoastrocytoma. *Acta Neuropathol* 2009;118:469-474

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann R, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. *J Clin Oncol* 2009;27:5874-5880

Roth P, Kissel M, Herrmann C, Eisele G, Leban J, Weller M, Schmidt F. SC68896, a novel small molecule proteasome inhibitor, exerts anti-glioma activity in vitro and in vivo. *Clin Cancer Res* 2009;15:6609-6618

Dumitru CA, Sandalcioglu IE, Wagner M, Weller M, Gulbins E. Lysosomal ceramide mediates

gemcitabine-induced death of glioma cells. *J Mol Med* 2009;87:1123-1132

Dumitru CA, Weller M, Gulbins E. Ceramide metabolism determines glioma cell resistance to chemotherapy. *J Cell Physiol* 2009;221:688-695

Bürk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, Rammensee HG, Oertel W. Neurological symptoms in patients with biopsy proven celiac disease. *Movement Disorders* 2009;24:2358-2362

Zieker D, Königsrainer I, Tritschler I, Löffler M, Beckert S, Traub F, Nieselt K, Bühler S, Weller M, Gaedcke J, Taichman RS, Northoff H, Brücher BL, Königsrainer A. Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. *Int J Cancer* 2010;126:1513-1520

Semmler A, Moskau S, Stoffel-Wagner B, Weller M, Linnebank M. The effect of MTHFR c.677 C>T on plasma homocysteine levels depends on health, age and smoking. *Clin Invest Med* 2009;32:E310

2010

Miller J, Eisele G, Tabatabai G, Aulwurm S, Noe-von Kürthy G, Stitz L, Roth P, Weller M. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. *J Neurosurg* 2010;113:280-285

Lanz T, Opitz Ch, Ho P, Agrawal A, Lutz Ch, Weller M, Mellor A, Steinmann L, Wick W, Platten M. Mouse mesenchymal stem cells suppress antigen-specific TH-cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1) *Stem Cells Dev* 2010;19:657-668

Dresemann G, Weller M, Rosenthal M, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, Schleyer E, Krex D, Olver I, Steinbach J, Hosius C, Sieder C, Sorenson G, Parker R, Nikolova Z. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive preterated glioblastoma resistant to standard dose temozolomide. *J Neuro-Oncol* 2010;96:393-402

Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. *J Neuro-Oncol* 2010;97:389-392

Maurer G, Schittenhelm J, Ernemann U, Kempf V, Ritz R, Weller M, Schmidt F. Intracranial hemangiomas in a patient with POEMS syndrome. *J Neurol* 2010;257:484-487

Klotz L, Farkas M, Bain N, Keskitalo S, Semmler A, Ineichen B, Jelcic J, Klockengether T, Kölsch H, Weller M, Linnebank M. The variant methylenetetrahydrofolate reductase c.1298>C (p.E429A) is associated with multiple sclerosis in a German case-control study. *Neurosci Lett* 2010;468:183-185

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, Grabenbauer GG, Ochsenein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krüger S, Picard M, Weller M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *J Clin Oncol* 2010;28:2712-2718

Brötz D, Maschke E, Burkard S, Engel C, Maenz C, Ernemann U, Wick W, Weller M. Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica? *Pain* 2010;149:470-475

Berger B, Capper D, Lemke D, Pfenning PN, Platten M, Weller M, von Deimling A, Wick W, Weiler M. Defective p53 antiangiogenic signaling in glioblastoma. *Neuro-Oncology* 2010;12:894-907

Hofer S, Linnebank M, Weller M. Cancer risk among patients with multiple sclerosis and their parents. *Neurology* 2010;74:614-615

Wick W, Puduvalli VK, Chamberlain M, Van den Bent M, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with

lomustine in the treatment of recurrent intracranial glioblastoma. *J Clin Oncol* 2010;28:1168-1174

Brötz D, Burkard S, Weller M. A prospective study of mechanical physiotherapy for lumbar disk prolapse: five-year follow-up and final report. *Neurorehabilitation* 2010;26:155-158

Valko P, Waldvogel D, Weller M, Bassetti C, Held U, Baumann C. Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. *Eur J Neurol* 2010;17:1428-1436

Wegener S, Bremer J, Komminoth P, Jung HH, Weller M. Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. *Case Rep Oncol* 2010;3:88-92

Linnebank M, Popp J, Smulders Y, Smith D, Semmler A, Farkas M, Kulic L, Cvetanovska G, Blom H, Stoffel-Wagner B, Kölsch H, Weller M, Jessen F. S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. *Neurodegenerative Dis* 2010;7:373-378

Temme A, Geiger KD, Wiedermuth R, Conseur K, Pietsch T, Felsberg J, Reifenberger G, Tatsuka M, Hagel C, Westphal M, Berger H, Simon M, Weller M, Schackert G. Giant cell glioblastoma is associated with altered Aurora B expression and concomitant p53 mutation. *J Neuropathol Exp Neurol* 2010;69:632-642

Tabatabai G, Hasenbach K, Herrmann C, Maurer G, Möhle R, Marini P, Grez M, Wick W, Weller M. Glioma tropism of lentivirally transduced hematopoietic progenitor cells. *Int J Oncol* 2010;36:1409-1417

Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. *Int J Rad Oncol Biol Phys* 2010;77:670-676

Roth P, Junker M, Tritschler I, Mittelbronn M, Dombrowski Y, Breit SN, Tabatabai G, Wick W, Weller M, Wischhusen J. GDF-15 contributes to proliferation and immune escape of malignant gliomas. *Clin Cancer Res* 2010;26:3851-3859

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Löffler M, von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavourable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathol* 2010;120:707-718

Heese O, Schmidt M, Nickel S, Berger H, Goldbrunner R, Tonn JC, Bähr O, Steinbach JP, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkha G, Löffler M, Weller M, Westphal M, for the German Glioma Network. Complementary therapy use in glioma patients. An observational study. *Neurology* 2010;75:2229-2235

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, Von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. G-PCNSL-SG-1 randomised phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma. *Lancet Oncol* 2010;11:1036-1047

2011

Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W, Weller M. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. *Neuro-Oncology* 2011;13:155-164

Wick A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M, Wick W. Bevacizumab does not increase the risk of remote relapse in malignant glioma. *Ann Neurol* 2011;69:586-592

- Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, Weller M, Elger CE. Antiepileptic drugs interact with folate and vitamin B12 serum levels. *Ann Neurol* 2011;69:352-359
- Kühnlein P, Jung H, Farkas M, Keskitalo S, Ineichen B, Jelcic I, Petersen J, Semmler A, Weller M, Ludolph AC, Linnebank M. The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is a possible risk factor for amyotrophic lateral sclerosis. *Amyotroph Lateral Scler* 2011;12:136-139
- Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Loeffler M, Weller M, Reifenberger G, Tonn JC, for the German Glioma Network. Promoter methylation and expression of *MGMT* and the DNA mismatch repair genes *MLH1*, *MSH2*, *MSH6*, and *PMS2* in paired primary and recurrent glioblastomas. *Int J Cancer* 2011;129:659-670
- Schittenhelm J, Simon P, Harter PN, Zachskorn C, Schlaszus H, Röttger F, Winkels M, Weller M, Meyermann R, Mittelbronn M. CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms. *Histopathology* 2011;58:739-749
- Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason WP, Belanger K, Brandes A, Bogdahn U, Macdonald D, Forsyth PA, Rossetti AO, Lacombe D, Miriamanoff RO, Vecht CJ, Stupp R. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. *Neurology* 2011;77:1156-1164
- Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Löffler M, Weller M, for the German Glioma Network. Molecular markers in low-grade gliomas: predictive or prognostic? *Clin Cancer Res* 2011;17:4588-4599
- Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenberger G, Weller M, Herrlinger U, for the German Neuro-Oncology Group of the German Cancer Society. NOA-05 phase II trial of procarbazine and CCNU therapy in gliomatosis cerebri. *Ann Neurol* 2011;70:445-453
- Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. *Acta Oncol* 2011;50:630-635
- Guzek M, Zorina O, Semmler A, Gonzenbach R, Huber M, Kullak-Ublick GA, Weller M, Russmann S. Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (ZHIAS). *Pharmacoepidemiol Drug Safety* 2011;20:930-938
- Roth P, Wischhusen J, Happold C, Anoop Chandran P, Hofer S, Eisele G, Weller M, Keller A. A specific miRNA signature in the peripheral blood of glioblastoma patients. *J Neurochem* 2011;118:449-457
- Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M, Wischhusen J. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. *Acta Neuropathol* 2011;122:353-365
- Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier CP, Meister G. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. *EMBO J* 2011;30:4309-4322
- Capper D, Simon M, Langhans CD, Okun JG, Tonn JC, Weller M, Von Deimling A, Hartmann C, for the German Glioma Network. 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. *Int J Cancer* 2012;131:766-768
- Opitz CA, Litztenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GG, Miller CL, Lutz C, Radlwimmer B, Lehmann I, Von Deimling A, Wick W, Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature* 2011;478:197-203

Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P. Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas - a prospective single-arm monocentric phase-II study (RNOP-05). *J Neuro-Oncol* 2011;104:801-809

2012

Bähr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Körtvelyessy P, Franz K, Tatagiba M, Seifert V, Weller M, Steinbach JP. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: The HELLO trial. *Acta Neurochir* 2012;154:229-235

Wanka C, Brucker DP, Bähr O, Ronellenfitch M, Weller M, Steinbach JP, Rieger J. Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. *Oncogene* 2012;31:3764-3776

Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T, Loeffler M, Weller M. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. *Int J Cancer* 2012;131:1342-1350

Hasenbach K, Wiehr S, Herrmann C, Mannheim J, Cay F, Von Kürthy G, Bolmont T, Grathwohl SA, Weller M, Lengerke C, Pichler BJ, Tabatabai G. Monitoring the glioma tropism of bone marrow-derived progenitor cells by two-photon laser scanning microscopy and positron emission tomography. *Neuro-Oncology* 2012;14:471-481

Hegi ME, Janzer RC, Lambiv WL, Gorlia T, Kouwenhoven MCM, Hartmann C, Von Deimling A, Martinet D, Besuchet Schmutz N, Diserens AC, Hamou MF, Bady P, Weller M, Van den Bent M, Mason WP, Mirimanoff RO, Stupp R, Mokhtari K, Wesseling P; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value. Central pathology review of the EORTC_26981 / NCIC_CE.3 trial. *Acta Neuropathol* 2012;123:841-852

Korfel A, Weller M, Martus P, Roth P, Klasen HA, Roeth A, Rauch M, Hertenstein B, Fischer T, Hundsberger T, Leithauser M, Birnbaum T, Kirchen H, Mergenthaler HG, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Fischer L. Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. *Ann Oncol* 2012;23:2374-2380

Christians A, Hartmann C, Benner A, Meyer M, von Deimling A, Weller M, Wick W, Weiler M. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. *PLoS One* 2012;7:e33449

Burger MC, Brucker DP, Baumgarten P, Ronellenfitch MW, Nordhammer C, Hasselblatt M, Eccles MR, Klingebiel T, Weller M, Rieger J, Mittelbronn M, Steinbach JP. PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. *Int J Oncol* 2012;41:235-241

Weller M, Martus P, Roth P, Thiel E, Korfel A, for the German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. *Neuro-Oncology* 2012;14:1481-1484

Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, Sokolov AA, Martin R, Weller M, Linnebank M. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. *Clin Neuropharmacol* 2012;35:77-80

Lemke D, Pfenning PN, Sahn F, Klein AC, Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M, Wick W. Costimulatory protein 41gB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. *Clin Cancer Res* 2012;18:105-117

Zorina OI, Haueis P, Semmler A, Marti I, Gonzenbach RR, Guzek M, Kullak-Ublick GA, Weller M,

Russmann S. Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. *Pharmacoepidemiol Drug Safety* 2012;21:872-80

Petersen JA, Jung HH, Weller M, Linnebank M. Autoimmune myasthenia gravis after sternal fracture. *Case Rep Neurol* 2012;4:20-22

Linnebank M, Moskau S, Semmler A, Widman G, Weller M, Kallweit U, Elger CE. Antiepileptic drugs and vitamin B6 plasma levels in adult patients. *Epilepsy Res* 2012;101:182-184

Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Roth A, Kaun S, Thiel E, Korfel A, Weller M. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. *Neurology* 2012;79:890-896

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, for the Neurooncology Working Group (NOA) of the German Cancer Society. Chemotherapy *versus* radiotherapy for malignant astrocytoma in the elderly. *Lancet Oncol* 2012;13:707-715

Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. *J Neurochem* 2012;122:444-455

Wolpert F, Roth P, Lamszus K, Tabatabai G, Weller M, Eisele G. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. *J Neuroimmunol* 2012;250:27-34

Riklin C, Seystahl K, Hofer S, Happold C, Winterhalder R, Weller M. Antiangiogenic treatment for multiple CNS hemangioblastomas. *Onkologie* 2012;35:443-445

Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M, Waldvogel D, Storch A, Baumann CR. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? *J Sleep Res* 2012;21:710-717

Taegtmeyer AB, Curkovic I, Corti N, Rosen C, Egbring M, Russmann S, Gantenbein AR, Weller M, Kullak-Ublick GA. Drug-related problems and factors influencing acceptance of clinical pharmacologists' alerts in a large cohort of neurology inpatients. *Swiss Med Weekly* 2012;142:13615

Bady P, Sciuscio D, Diserens AC, Bloch J, Van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani M, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. *Acta Neuropathol* 2012;124:547-560

2013

Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. *Eur Neurol* 2013;69:95-101

Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, Krex D, Reithmeier T, Kowoll A, Weller M, Wick W. A comprehensive analysis of vascular complications in 3889 glioma patients from the German Glioma Network. *J Neurol* 2013;260:847-855

Spescha RD, Shi Y, Wegener S, Keller S, Weber B, Wyss MM, Lauinger N, Tabatabai G, Paneni F, Cosentino F, Hock C, Weller M, Nitsch RM, Lüscher TF, Camici GG. Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. *Eur Heart J* 2013;34:96-103

Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H,

Tritschler I, Weller M. Integrin control of the transforming growth factor- β pathway in glioblastoma. *Brain* 2013;136:564-576

Weiler M, Pfenning PN, Thiepold AL, Jestaedt L, Gronych J, Dittmann L, Berger B, Jugold M, Kosch M, Weller M, Combs SE, von Deimling A, Bendszus M, Platten M, Wick W. Suppression of invasion-driving RGS4 by radiation-enhanced mTOR inhibition optimizes antiangiogenesis. *Oncogene* 2013;32:1099-1109

Schreglmann SR, Jelčić I, Taegtmeyer AB, Linnebank M, Weller M. Multifocal CNS demyelination after octreotide treatment for metastatic meningioma. *Clin Neurol Neurosurg* 2013;115:817-819

Mittelbronn M, Warth A, Meyermann R, Goodman S, Weller M. Expression of integrins $\alpha v\beta 3$ and $\alpha v\beta 5$ and their ligands in primary and secondary central nervous system neoplasms. *Histol Histopathol* 2013; 28:749-758

Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, Müller CP, Tischbirek CH, Groemer TW, Tabatabai G, Becker KA, Tripal P, Staedtler S, Ackermann TF, Van Brederode K, Alzheimer C, Weller M, Lang UE, Kleuser B, Grassmé H, Kornhuber J. Acid sphingomyelinase/ceramide system mediates effects of antidepressant drugs. *Nat Med* 2013;19:934-938

Gramatzki D, Herrmann C, Happold C, Becker KA, Gulbins E, Weller M, Tabatabai G. Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway. *PLoS One* 2013;e63527

Gonzenbach RR, Kong Y, Beck B, Buck A, Weller M, Semmler A. High-dose praziquantel therapy for cerebral sparganosis. *J Neurol* 2013;260:1423-1425

Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman S, Moch H. αv -Integrin isoform expression in primary human tumors and brain metastases. *Int J Cancer* 2013;133:2362-2371

Wegener S, Artmann J, Luft AR, Buxton RB, Weller M, Wong EC. The time of maximum post-ischemic hyperperfusion indicates infarct growth following transient experimental ischemia. *PLoS One* 2013;8:e65322

Heese O, Vogeler E, Martens T, Schnell O, Tonn JC, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkhah G, Sabel M, Steiger HJ, Schlegel U, Löffler M, Weller M, Westphal M, for the German Glioma Network. End of life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. *Neuro-Oncology* 2013;15:1251-1256

Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W; for the Neuro-oncology Working Group (NOA) of the German Cancer Society. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. *Neuro-Oncology* 2013;15:1017-1026

Schippling S, Kempf C, Büchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, Martin R. JCV granule cell neuronopathy and GCN-IRIS in multiple sclerosis under natalizumab. *Ann Neurol* 2013;74:622-626

Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M. Invasion patterns in brain metastases of solid cancers. *Neuro-Oncology* 2013;15:1664-1672

Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel M, Koeppen S, Ketter R, Weiler M, Tabatabai G, Von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. *Neurology* 2013;81:1515-1522

Eisele G, Wolpert F, Decrey G, Weller M. APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. *Anticancer Res* 2013;33:3563-3571

Wiestler B, Capper D, Holland-Letz T, Korshunov A, Von Deimling A, Pfister SM, Platten M, Weller M, Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of *IDH* mutant astrocytic tumors with better prognosis. *Acta Neuropathol* 2013;126:443-451

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger R, Pietsch T, von Deimling A, Weller M, for the German Glioma Network. Longterm survival in primary glioblastoma with *versus* without isocitrate dehydrogenase mutations. *Clin Cancer Res* 2013;19:5146-5157

Goeppert B, Schmidt CR, Geiselhart L, Dutruel C, Capper D, Renner M, Vogel MN, Zachskorn C, Zinke J, Campos B, Schmezer P, Popanda O, Wick W, Weller M, Meyermann R, Schittenhelm J, Harter PN, Simon P, Weichert W, Schirmacher P, Plass C, Mittelbronn M. Differential expression of the tumor suppressor A kinase anchor protein 12 (AKAP12) in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. *J Neuropathol Exp Neurol* 2013;72:933-941

Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC. Gross total but not incomplete resection of GBM prolongs survival in the era of radiochemotherapy. *Ann Oncol* 2013;24:3117-3123

Vom Berg J, Vrohling M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B. T cells are crucial effectors of glioma rejection induced by local IL-12 application and can be further boosted by CTLA-4 blockade. *J Exp Med* 2013;210:2803-2811

Fan QW, Cheng C, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. *Cancer Cell* 2013;24:438-449

Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DTW, Kool M, Northcott PA, Wiestler B, Böhmer B, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A. Distribution of *TERT* promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathol* 2013;126:907-915

2014

Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, Von Deimling A, Davis T, Weiss WA, Loeffler M, Reifenberger G, for the German Glioma Network. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. *Int J Cancer* 2014;134:2437-2447

Wirsching HG, Krishnan S, Florea AF, Frei K, Krayenbühl N, Hasenbach K, Reifenberger R, Weller M, Tabatabai T. Thymosin-β4 gene silencing decreases stemness and invasiveness in glioblastoma. *Brain* 2014;137:433-448

Rossetti A, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. *Neuro-Oncology* 2014;16:584-588

Tonder M, Rushing EJ, Grotzer M, Sürücü O, Valavanis A, Buck A, Weller M, Roth P. A 30-year-old woman with recurrent seizures and a cerebral lesion progressing over 2 decades. *Neurology* 2014;82:e56-60

Wolpert F, Tritschler I, Steinle A, Weller M, Eisele G. A disintegrin and metalloproteinases (ADAM) 10 and 17 modulate the immunogenicity of glioblastoma stem cells. *Neuro-Oncology* 2014;16:382-391

Silginer M, Weller M, Ziegler U, Roth P. Integrin inhibition promotes atypical anoikis in glioma cells. *Cell Death Dis* 2014;5:e1012

Weiler W, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker SC, Osswald M, Meisner M, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schölzer M, Abdollahi A, Lang F, Bendszus M, Von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W. The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. *Proc Natl Acad Sci USA* 2014;111:409-414

Seystahl K, Weller M, Bozinov, Reimann R, Rushing E. Neuropathological characteristics of progression after prolonged response to bevacizumab in multifocal hemangioblastoma. *Onkologie* 2014;37:209-212

Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, Schackert G, Tatagiba M, Westphal M, Tonn JC, Gramatzki D, Pietsch T, Hartmann C, Glimm H, Vajkoczy P, von Deimling A, Platten M, Weller M, Wick W. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. *J Neuro-Oncol* 2014;117:25-32

Ineichen BV, Keskitalo S, Farkas M, Bain N, Kallweit U, Weller M, Klotz L, Linnebank M. Genetic variants of homocysteine metabolism and multiple sclerosis: A case-control study. *Neurosci Lett* 2014;562:75-78

Eisele G, Wick A, Eisele AC, Clement PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. *J Neuro-Oncol* 2014;117:141-145

Valavanis A, Schwarz U, Baumann C, Weller M, Linnebank M. Amyotrophic lateral sclerosis after embolisation of cerebral arteriovenous malformations. *J Neurol* 2014;261:732-737

Haertle M, Kallweit U, Weller M, Linnebank M. The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases. *J Neurol* 2014;261:554-560

Branscheidt M, Frontzek K, Bozinov O, Valavanis A, Rushing ER, Weller M, Wegener S. Etoposide/carboplatin chemotherapy for the treatment of metastatic myxomatous cerebral aneurysms. *J Neurol* 2014;261:828-830

Happold C, Roth P, Silginer M, Florea AM, Lamszus K, Frei K, Deenen R, Reifenberger G, Weller M. Interferon- β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. *Mol Cancer Ther* 2014;13:948-961

Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M, for the German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. *Int J Cancer* 2014;135:1822-1831

Riehmer V, Gietzelt J, Beyer U, Hentschel B, Westphal M, Schackert G, Sabel MC, Radlwimmer B, Pietsch T, Reifenberger G, Weller M, Weber RG, Loeffler M, for the German Glioma Network. Genomic profiling reveals three molecular relapse patterns in IDH1/2 wild-type glioblastoma. *Genes, Chromosomes & Cancer* 2014;53:589-605

Fischer S, Ronellenfitsch MW, Thiebold AL, Harter PN, Reichert S, Kögel D, Paschke R, Mittelbronn M, Weller M, Steinbach JP, Fulda S, Bähr O. Hypoxia enhances the anti-glioma cytotoxicity of B10, a glycosylated derivative of betulinic acid. *PLoS One* 2014;9:e94921

Hundsberger T, Tonder M, Hottinger A, Brüggel D, Roelcke U, Putora PM, Stupp R, Weller M. Clinical

management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. *J Neuro-Oncol* 2014;118:321-328

Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP. ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. *Int J Oncol* 2014;44:1843-1852

Tonder M, Eisele G, Weiss T, Hofer S, Seystahl K, Valavanis A, Stupp R, Weller M, Roth P. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. *Acta Oncol* 2014;26:1-4

Bracko O, Di Pietro V, Lazzarino G, Amorini AM, Tavazzi B, Artmann J, Wong EC, Buxton RB, Weller M, Luft AR, Wegener S. 3-nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow. *J Cerebral Blood Flow Metab* 2014;34:1522-1530

Wiestler B, Capper D, Sill M, Jones DTW, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Alexander Radbruch A, Herold-Mende C, Roth P, Unterberg A, Hartmann C, Pietsch P, Reifenberger G, Lichter L, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W. Integrated DNA methylation and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic glioma. *Acta Neuropathol* 2014;128:561-571

Wiestler B, Capper D, Hovestadt V, Sill M, Jones DTW, Hartmann C, Felsberg J, Platten M, Feiden WE, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W. Assessing CpG island methylator phenotype, 1p/19q codeletion and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. *Neuro-Oncology* 2014;16:1630-1638

Lemke D, Weiler M, Blaes J, Wiestler B, Jestaedt L, Klein AC, Löw S, Eisele G, Radlwimmer B, Capper D, Schmieder K, Mittelbronn M, Combs SE, Bendszus M, Weller M, Platten M, Wick W. Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity? *J Neurochem* 2014;131:251-254

Stupp R, Hegi ME, Gorlia T, Erridge S, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujcic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJB, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CK, Nabors LB, Reardon DA, Van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M, on behalf of European Organisation for Research and Treatment of Cancer (EORTC), the Canadian Brain Tumor Consortium, and the CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter: final results of the multicentre, randomised, open-label, controlled, phase 3 CENTRIC (EORTC 26071-22072) study. *Lancet Oncol* 2014;15:1100-1108

Seystahl K, Tritschler I, Szabo E, Tabatabai G, Weller M. Differential regulation of TGF- β -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. *Neuro-Oncology* 2015;17:254-265

Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, Reifenberger G, Roth P. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. *Oncotarget* 2014;5:7651-7662

Wegener S, Linnebank M, Martin R, Valavanis A, Weller M. Clinically isolated neurosarcoidosis: a recommended diagnostic path. *Eur Neurol* 2014;73:71-77

Berghoff AS, Kovanda AK, Melchardt T, Bartsch R, Hainfellner JA, Sipos B, Schittenhelm J, Zielinski CC, Widhalm G, Dieckmann K, Weller M, Goodman SL, Birner P, Preusser M. $\alpha\beta 3$, $\alpha\beta 5$ and $\alpha\beta 6$ integrins in brain metastases of lung cancer. *Clin Exp Metastasis* 2014;31:841-851

Wirsching HG, Tritschler I, Palla A, Renner C, Weller M, Tabatabai G. The management of lomustine overdose in malignant glioma patients. *Neuro-Oncol Pract* 2014;1:178-183

Keskitalo S, Farkas M, Hanenberg M, Szodorai A, Kulic L, Semmler A, Weller M, Nitsch RM, Linnebank M. Reciprocal modulation of A β 42 aggregation by copper and homocysteine. *Frontiers in Aging Neuroscience* 2014;6:237

2015

Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, Lutz J, Egensperger R, Giese A, Herms J, Weller M, Kretschmar H, Tonn JC, La Fougere C, Kreth FW. Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. *Int J Cancer* 2015;136:2132-2145

Ahmad A, Frei K, Willscher E, Stefanski A, Kaulich K, Roth P, Stühler K, Reifenberger G, Binder H, Weller M. How stem-like are sphere cultures from long-term cancer cell lines: lessons from mouse glioma models. *J Neuropathol Exp Neurol* 2014;73:1062-1077

Kreher S, Strehlow F, Martus P, Roth P, Hertenstein B, Röth A, Birnbaum T, Griesinger F, Rauch M, Kanz L, Thiel E, Weller M, Korfel A. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. *Ann Hematol* 2015;94:409-414

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. *Neuro-Oncology* 2015;17:1064-1075

Suchorska B, Jansen NL, Linn J, Kretschmar H, Janssen H, Eigenbrod S, Simon M, Pöpperl G, Kreth FW, La Fougere C, Weller M, Tonn JC, for the German Glioma Network. Biological tumor volume in 18FET-PET prior to radio-chemotherapy correlates with survival in GBM. *Neurology* 2015;84:710-719

Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M. Differentially regulated miRNAs as prognostic biomarkers in the blood of PCNSL patients. *Eur J Cancer* 2015;51:382-390

Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M, for the German PCNSL Study Group. Randomized phase III study of radiotherapy for primary cerebral lymphoma. *Neurology* 2015;84:1242-1248

Reuss DE, Sahn F, Schrimpf D, Wiestler B, Capper D, Kölsche C, Schweizer L, Korshunov A, Jones DTW, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated“ diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathol* 2015;129:133-146

Ulrich A, Weiler S, Weller M, Rordorf T, Tarnutzer AA. Cetuximab induced aseptic meningitis - case report and review of the literature. *J Clin Neurosci* 2015;22:1061-1063

Kurscheid S, Bady P, Sciuscio D, Samarzija I, Shay T, Vassallo I, Van Criekinge W, Daniel RT, Van den Bent MJ, Marosi C, Weller M, Mason WP, Domany E, Stupp R, Delorenzi M, Hegi ME. Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. *Genome Biol* 2015;16:16

Lassen U, Chinot OL, McBain C, Mau-Sørensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, Tessier J, Lahr A, Weller M. Phase I dose-escalation study of the anti-placental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. *Neuro-Oncology* 2015;17:1007-1015

Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, Rushing EJ, Weller M. Transforming growth factor- β pathway activity in glioblastoma. *Oncotarget* 2015;6:5963-5977

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger R, Wick W, for the DIRECTOR Study Group. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. *Clin Cancer Res* 2015;21:2057–2064

Kreher S, Jöhrens K, Strehlow F, Martus P, Borowiec K, Radke J, Heppner F, Roth P, Thiel E, Pietsch T, Weller M, Korfel A. Prognostic impact of BCL-6 in primary CNS lymphoma. *Neuro-Oncology* 2015;17:1016-1021

Weller M, Weber RG, Willscher E, Riehm V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach J, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G, for the German Glioma Network. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. *Acta Neuropathol* 2015;129:679–693

Wörnle CM, Péus D, Hofer S, Rushing EJ, Held U, Bozinov O, Krayenbühl N, Weller M, Regli L. Efficacy of surgery and further treatment of progressive glioblastoma. *World Neurosurg* 2015;84:301-307

Traber GL, Pangalu A, Neumann M, Costa J, Weller M, Huna-Baron R, Landau K. Malignant optic glioma – the spectrum of disease in a case series. *Graefe's Arch Clin Exp Ophthalmol* 2015;253:1187-1189

Krishnan S, Szabo E, Tritschler I, Frei K, Tabatabai G, Weller M. Modulation of cerebral endothelial cell function by TGF- β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition. *Oncotarget* 2015;6:22480-22495

Reuss DE, Kratz A, Sahm F, Capper D, Schimpf D, Koelsche C, Hovestadt V, Bewerunge-Hudler M, Jones DT, Schittenhelm J, Mittelbronn M, Rushing E, Simon M, Westphal M, Unterberg A, Platten M, Paulus W, Reifenberger G, Tonn JC, Aldape K, Pfister SM, Korshunov A, Weller M, Herold-Mende C, Wick W, Brandner S, von Deimling A. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. *Acta Neuropathol* 2015;130:407-417

Furtner J, Schöpf V, Seystahl K, Le Rhun E, Rudà R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffiatti R, Weller M, Preusser M. Kinetics of tumor size and peritumoral brain edema before, during and after systemic therapy in recurrent WHO grade II or III meningioma. *Neuro-Oncology* in press

Tonder M, Weller M, Eisele G, Roth P. Carboplatin and etoposide in heavily pre-treated patients with progressive high-grade glioma. *Chemotherapy* 2014;60:375-378

Silginer M, Burghardt I, Gramatzki D, Bunse L, Leske L, Rushing EJ, Hao N, Platten P, Weller M, Roth P. The aryl hydrocarbon receptor links integrin signaling to the TGF- β pathway. *Oncogene* in press

Wolpert F, Happold C, Reifenberger G, Florea AM, Deenen R, Roth P, Lamszus K, Westphal M, Neidert N, Weller M, Eisele G. Interferon- β modulates the innate immune response against glioblastoma initiating cells. *PLoS One* 2015;10:e0139603

Kumar KS, Pillong M, Kunze J, Burghardt I, Weller M, Grotzer MA, Schneider G, Baumgartner M. Computer-assisted quantification of motile and invasive capabilities of cancer cells. *Sci Rep* 2015;5:15338

Hundsberger T, Hottinger AF, Roelcke U, Roth P, Migliorini D, Dietrich PY, Conen K, Pesce G, Hermann E, Pica A, Gross MW, Brügge D, Plasswilm L, Weller M, Putora PM. Patterns of care in recurrent glioblastoma in Switzerland - a multicentre national approach based on diagnostic nodes. *J*

Herrlinger U, Jones DTW, Glas M, Hattungen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen G, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G. Gliomatosis cerebri: No evidence for a separate brain tumor entity. *Acta Neuropathol* in press

Roelcke U, Wyss MT, Nowosielski M, Rudà R, Roth P, Hofer S, Galldiks N, Crippa F, Weller M, Soffietti R. Amino acid PET to monitor chemotherapy response, and to predict seizure control and progression-free survival in WHO grade II gliomas. *Neuro-Oncology* in press

Happold C, Gorlia T, Chinot O, Gilbert M, Nabors B, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon D, Perry JR, Mehta M, Stupp R, Weller M. Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma. *J Clin Oncol* 2016;34:731-739

Wirsching HG, Morel M, Gmür C, Neidert MC, Baumann CR, Valavanis A, Rushing ER, Krayenbühl N, Weller M. Predicting outcome of epilepsy after meningioma resection. *Neuro-Oncology* in press

Codo P, Weller M, Kaulich K, Schraivogel D, Silginer M, Reifenberger G, Meister G, Roth P. Control of glioma cell migration and invasiveness by GDF-15. *Oncotarget* in press

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HW. Complete resection of contrast enhancing tumor volume is associated with improved survival in recurrent glioblastoma— results from the DIRECTOR trial. *Neuro-Oncology* 2016;18:549-566

Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, Weller M, Schaefer N, Kuhn FP. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? *Neuro-Oncology* in press

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambarzumyan D. Corticosteroids compromise survival in glioblastoma. *Brain* in press

Stojcheva N, Schechtmann G, Sass S, Roth P, Florea AF, Stefanski A, Stühler K, Wolter M, Müller NS, Theis FJ, Weller M, Reifenberger G, Happold C. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. *Oncotarget* in press

Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman S, Hegi M, Picard M, Moch H, Straub J, Stupp R. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. *Oncotarget* in press

Fierstra J, Van Niftrik B, Piccirelli M, Burkhardt JK, Pangalu A, Kocian R, Valavanis A, Weller M, Regli L, Bozinov O. Altered intraoperative cerebrovascular reactivity in brain areas of high-grade glioma recurrence. *Magnetic Resonance Imaging* in press

Gramatzki D, Dehler S, Rushing EJ, Zaugg K, Hofer S, Yonekawa Y, Bertalanffy H, Valavanis A, Korol D, Rohrman S, Pless M, Oberle J, Roth P, Ohgaki H, Weller M. Glioblastoma in the Canton of Zurich, Switzerland, revisited (2005-2009). *Cancer* in press

Szabo E, Schneider H, Seystahl K, Rushing EJ, Herting F, Weidner KM, Weller M. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. *Neuro-Oncology* in press

Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, Ilhan H, Pangalu A, Weller M, Tonn JC, Sommerauer M, Albert NL. Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma - benefit linked to ⁶⁸Ga-DOTATATE/-TOC uptake. Neuro-Oncology in press

Gramatzki D, Roth P, Felsberg J, Hofer S, Rushing EJ, Hentschel B, Westphal M, Krex D, Simon M, Schnell O, Wick W, Reifenberger G, Weller M. Chemotherapy for intracranial ependymoma in adults. BMC Cancer in press

Mangani D, Weller M, Seyed Sadr E, Willscher E, Seystahl K, Reifenberger G, Tabatabai G, Binder H, Schneider H. Limited role for transforming growth factor- β pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro-Oncology in press

Schneider H, Weller M. Boswellic acid activity against glioblastoma stem-like cells. Oncol Rep in press

Reviews and Correspondence

1988

Wiedemann P, Weller M. The pathophysiology of proliferative vitreoretinopathy. *Acta Ophthalmol* 1988;66(Suppl. 189):7-15

1989

Weller M, Heimann K, Wiedemann P. Immunochemical analysis of periretinal membranes. Review and outlook. *Dev Ophthalmol* 1989;16:54-74

Weller M, Wiedemann P. Visual hallucinations. An outline of etiological and pathogenetic concepts. *Int Ophthalmol* 1989;13:193-199

Weller M, Wiedemann P. Hysterical symptoms in ophthalmology. *Doc Ophthalmol* 1989;73:1-33

1990

Weller M, Heimann K, Wiedemann P. Mononukleäre Phagozyten und ihre Wachstumsfaktoren: Schrittmacher der proliferativen Vitreoretinopathie? *Klein Monatsbl Augenheilkd* 1990;196:121-127

Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathy. Is it anything more than wound healing at the wrong place? *Int Ophthalmol* 1990;14:105-117

Weller M, Heimann K, Wiedemann P. The pathogenesis of vitreoretinal proliferation and traction. *Med Hypotheses* 1990;31:157-159

Wiedemann P, Weller M, Heimann K. Proliferative Vitreoretinopathie: Neue Erkenntnisse in Pathophysiologie und Therapie. *Klein Monatsbl Augenheilkd* 1990;197:355-361

1991

Weller M, Wiedemann P, Heimann K. Humorale Faktoren in der Genese der proliferativen Vitreoretinopathie: zur Bedeutung der Integrität der Blut-Retina-Schranke. *Spektrum Augenheilkd* 1991;5/6:245-247

Weller M, Esser P, Heimann K, Wiedemann P. Mononuclear phagocytes in proliferative vitreoretinopathy (PVR). A specific role of microglial cells in non-traumatic disease? *Eur J Ophthalmol* 1991;1:161-166

1992

Weller M. Diagnostic value of fibronectin determination in the CSF. *J Clin Pathol* 1992;45:548-549

Weller M. Elevated levels of fibronectin in the CSF: what do they signify? *J Neurol Sci* 1992;110:232-233

Weller M. How to define the opercular syndrome? *J Neurol* 1992;239:294-295

Weller M. Anti-Phospholipid-Antikörper und zerebrale Ischämie. *Fortschr Neurol Psychiatr* 1992;60:246-247

Weller M. The age of Karl Ludwig Kahlbaum. *Biol Psychiatry* 1992;32:213-214

Weller M, Kornhuber J. Elektrokonvulsionstherapie: Fehlerquellen und Hilfsmaßnahmen bei insuffizienter Konvulsionsdauer. *Fortschr Neurol Psychiatr* 1992;60:223-226

Weller M. NMS and lethal catatonia. *J Clin Psychiatry* 1992;53:294

Weller M, Kornhuber J. N-methyl-D-aspartate antagonists, schizophrenia, and neuroleptic malignant syndrome. *Arch Neurol* 1992;49:900-901

Weller M, Kornhuber J. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. *Med Hypotheses* 1992;38:329-333

Weller M, Kornhuber J. Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. *Nervenarzt* 1992;63:645-655

1993

Weller M, Kornhuber J. Does clozapine cause neuroleptic malignant syndrome? *J Clin Psychiatry* 1993;54:70-71

Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic Parkinsonian crisis. *J Neural Transmission [P-D Sect]* 1993;6:63-72

Weller M, Kornhuber J. Amantadine withdrawal and neuroleptic malignant syndrome. *Neurology* 1993;43:2155

Weller M. Anterior opercular cortex lesions cause dissociated lower cranial nerve palsies and anarthria but no aphasia. Foix-Chavany-Marie syndrome and "automatic voluntary dissociation" revisited. *J Neurol* 1993;240:199-208

Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. *Doc Ophthalmol* 1993;84:309-333

1994

Kornhuber J, Weller M. Neuroleptic malignant syndrome. *Curr Opin Neurol* 1994;7:353-357

Kornhuber J, Weller M. Clozapin (Leponex®). *Intern Prax* 1994;34:656-660

Kornhuber J, Weller M. Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien. *Nervenarzt* 1994;65:741-754

Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. *J Neural Transmission* 1994;Suppl. 43:91-104

1995

Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF- β , T cell apoptosis, and the immune privilege of the brain. *Brain Res Rev* 1995;21:128-151

1996

Kornhuber J, Weller M. Neue therapeutische Möglichkeiten mit niederaffinen NMDA-Rezeptorantagonisten. *Nervenarzt* 1996;67:77-82

Weller M, Kornhuber J. Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report. *Austr N Z J Med* 1996;26:232-233

Weller M. Genetic regulation and therapeutic modulation of apoptosis in human malignant glioma. *Cell Physiol Biochem* 1996;6:376-380

1997

Weller M, Kornhuber J. Clozapine and NMS: a never-ending story. *J Clin Psychopharmacol* 1997;17:233

Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. *Biol Psychiatry* 1997;41:135-144

Schabet M, Herrlinger U, Weller M, Bamberg M, Clemens R, Dichgans J. Neue Entwicklungen in Diagnostik und Therapie primärer Non-Hodgkin-Lymphome des zentralen Nervensystems. *Nervenarzt* 1997;68:298-308

Kornhuber J, Weller M. Das maligne neuroleptische Syndrom. *Aktuel Neurol* 1997;24:129-133

Weller M, Schulz JB, Wüllner U, Löschnann P, Klockgether T, Dichgans J. Developmental and genetic regulation of programmed neuronal death. *J Neural Transmission* 1997;Suppl. 50:115-123

1998

Weller M. Assessing response to chemotherapy in malignant glioma: the role of steroids. *Neurology* 1998;50:1196

Weller M. Predicting response to cancer chemotherapy: the role of p53. *Cell Tissue Res* 1998;292:435-445

Weller M, Kleihues P, Dichgans J, Ohgaki H. CD95 ligand: lethal weapon for malignant glioma? *Brain Pathol* 1998;8:285-293

Weller M, Dichgans J. Erstbeschreibung des Ross-Syndroms durch Hans Huetlin. *Nervenarzt* 1998;69:540

Herrlinger, Weller M, Schabet M. New aspects of immunotherapy of leptomeningeal metastasis. *J Neuro-Oncol* 1998;38(Suppl.):233-239

Zipp F, Martin R, Dichgans J, Weller M. CD95 (Fas/APO-1) and Parkinson's disease: reply. *Ann Neurol* 1998;44:426

1999

Ständer M, Naumann U, Wick W, Weller M. TGF- β and p21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. *Cell Tissue Res* 1999;296:221-227

Schulz JB, Weller M, Moskowitz M. Caspases as treatment targets in stroke and neurodegenerative diseases. *Ann Neurol* 1999;45:421-429

Zipp F, Krammer PH, Weller M. Immune (dys)regulation in multiple sclerosis: role of the CD95/CD95 ligand system? *Immunol Today* 1999;20:550-554

Rieger J, Roth W, Glaser T, Winter S, Rieger L, Dichgans J, Weller M. Glioblastoma multiforme: mechanisms of resistance to chemotherapy. *Neurol Psychiatr Brain Res* 1999;7:37-46

Roth W, Weller M. Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. *Cell Mol Life Sci* 1999;56:481-506

Weller M. Glucocorticoid treatment of primary CNS lymphoma. *J Neuro-Oncol* 1999;43:237-239

2000

Weller M. Chemotherapie maligner Gliome. *Nervenheilkunde* 2000;19:116-120

Weller M, Reed JC. Apoptosis 2000. Preface. Cell Tissue Res 2000;301:3

2001

Weller M, Wick W, Platten M. Role of TGF- β in oncogenesis (Editorial). Microscop Res Technol 2001;52:353

Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF- β in growth, motility, angiogenesis and immune escape. Microscop Res Technol 2001;52:401-410

Weller M, Thömke F. Meningeosis neoplastica. Aktuel Neurol 2001;28:265-272

2002

Steinbach JP, Weller M. Mechanisms of apoptosis in central nervous system tumors: application to theory. Curr Neurol Neurosci Rep 2002;2:246-253

Bögler O, Weller M. Apoptosis in glioma, and its role in their current and future treatment. Front Biosci 2002;7:E339-353

Plasswilm L, Herrlinger U, Korfel A, Weller M, Küker W, Kanz L, Thiel E, Bamberg M. Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol 2002;81:415-423

2003

Waltereit R, Weller M. Signaling from Camp/PKA to MAPK and synaptic plasticity. Mol Neurobiol 2003;27:99-106

Bögler O, Weller M. Meeting Report: International Hermelin Brain Tumor Center Symposium on Apoptosis. Cell Death Differ 2003;10:1112-1115

Wiendl H, Mitsdörffer M, Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 2003;13:343-351

Kortmann RD, Jeremic B, Weller M, Plasswilm L, Bamberg M. Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol 2003;179:219-232

Weller M. Differentialdiagnose und medikamentöse Therapie neurogener Blasenstörungen. Aktuel Neurol 2003;30:382-389

Weller M. Modulation der Apoptosevulnerabilität und Motilität von Glioblastomzellen durch Gammastrahlung. Mol Radiat Biol Oncol 2003;4:57-59

Wiendl H, Mitsdörffer M, Weller M. Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. Human Immunol 2003;64:1050-1056

Weller M. Neuroonkologie. Nervenarzt 2003;74:1139-1149

2004

Steinbach JP, Weller M. Apoptosis in gliomas: Molecular mechanisms and therapeutic implications. J Neuro-Oncol 2004;70:245-254

Weller M. Therapeutische Antagonisierung von transforming growth factor- β (TGF- β) beim Glioblastom: Rationale und aktuelle Behandlungskonzepte. Aktuel Neurol 2004;31:14-18

Naumann U, Wick W, Beschorner R, Meyermann R, Weller M. Osteoprotegerin in the central nervous system. Acta Neuropathol 2004;107:578

Friese MA, Steinle A, Weller M. The innate immune response in the central nervous system and its role in glioma immune surveillance. *Onkologie* 2004;27:487-491

Kortmann RD, Jeremic B, Weller M, Lutterbach J, Paulsen F, Bamberg M. Immediate postoperative radiotherapy or "watch and wait" in the management of adult low-grade glioma? *Strahlenther Onkol* 2004;180:408-418

2005

Herrlinger U, Korfel A, Hebart H, Schlegel U, Plasswilm L, Illerhaus G, Finke J, Krüger W, Montemurro M, Wolf T, Thiel E, Bamberg M, Weller M, Kanz L. Primary central nervous system lymphoma: standards of care and future perspectives. Meeting report. *Onkologie* 2005;28:109-111

Brötz D, Weller M. A prospective trial of mechanical physiotherapy for lumbar disk prolapse (Response). *J Neurol* 2005;253:118

Weller M. Standards und neue Entwicklungen bei der Chemotherapie des Glioblastoms. *Dtsch Med Wschr* 2005;130:2270-2274

Weller M, Steinbach JP, Wick W. Temozolomide: a milestone in the pharmacotherapy of brain tumors. *Future Oncol* 2005;1:747-754

2006

Wick W, Naumann U, Weller M. Transforming growth factor- β : a molecular target for the future therapy of glioblastoma. *Curr Pharm Design* 2006;12:341-349

Stupp R, Hegi ME, Van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG, on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada (NCIC) Clinical Trials Group. Changing paradigms. An update on the multidisciplinary management of malignant glioma. *Oncologist* 2006;11:165-180

2007

Diener HC, Elger CE, Hartung HP, Maschke M, Weller M, Deuschl G, Kastrup O, Schuchardt V. Off label use in der Neurologie. *Aktuel Neurol* 2007;34:75-79

Weller M. Radiochemotherapy for brain metastasis: how to define a role for temozolomide. *Onkologie* 2007;30:350-351

Weller M. Diagnostische und therapeutische Strategien bei rezidivierten Gliomen. *Aktuel Neurol* 2007;34:564-569

2008

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. *J Clin Oncol* 2008;26:4189-4199

Weller M. Chemotherapie von Hirntumoren des Erwachsenenalters. *Nervenarzt* 2008;79:231-241

Semmler A, Köhler W, Jung HH, Weller M, Linnebank M. Therapy of X-linked adrenoleukodystrophy. *Expert Rev Neurother* 2008;8:1367-1379

Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. *Clin Cancer Res* 2008;14:2900-2908

Weller M, Yung WKA. Bevacizumab – News from the fast lane? *Neuro-Oncology* 2008;10:647

2009

Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. *Neuro-Oncology* 2009;11:69-79

Diener HC, Hartung HP, Bien CG, Hacke W, Ringelstein EB, Ludolph A, Deuschl G, Wiltfang J, Weller M, Steinhausen K, Stemper B, Klatt J, Drepper J, Griewing B, Meier U, Herschel M, Hummel K, Paar WD, Dintsios CM, Schade-Brittinger C, Weber R, Weimar C. Klinische Studien in der Neurologie in Deutschland 2008. *Aktuel Neurol* 2009;36:8-18

Weller M, Aguzzi A. Movement disorders reveal Creutzfeldt-Jakob disease. *Nature Rev Neurol* 2009;5:185-186

Weller M, Reardon D, Nabors B, Stupp R. Will integrin inhibitors have proangiogenic effects in the clinic. *Nature Med* 2009;15:726-727

Weller M, Stupp R. Approval of new drugs for glioblastoma. *Curr Opin Neurol* 2009;22:617-618

Wick W, Weller M. Classification and management of anaplastic gliomas. *Curr Opin Neurol* 2009;22:650-656

2010

Weller M, Stupp R, Reifenberger G, Brandes AA, Van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? *Nature Rev Neurol* 2010;6:39-51

Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant gliomas: a European perspective. *J Clin Oncol* 2010;28:e188-189

Weller M. Temozolomide and MGMT forever? *Neuro-Oncology* 2010;12:219-220

Weller M. Immunotherapy for glioblastoma: a long and winding road. *Neuro-Oncology* 2010;12:319

Weller M. Angiogenesis in glioblastoma: just another moving target? *Brain* 2010;133:955-956

Wick W, Weller M. Strukturen neuroonkologischer Forschung und Versorgung. *Nervenarzt* 2010;81:911-912

Wick W, Weller M. Anaplastische Gliome: Neuropathologie, molekulare Diagnostik und aktuelle Studienkonzepte. *Nervenarzt* 2010;81:928-935

Weller M. Chemotherapy for low-grade gliomas: When? How? How long? *Neuro-Oncology* 2010;12:1013

Tabatabai G, Weller M, Nabors B, Picard M, Reardon M, Mikkelsen T, Ruegg C, Stupp R. Targeting integrins in malignant glioma. *Targ Oncol* 2010;5:175-181

Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M. Molecular diagnostics of gliomas: the clinical perspective. *Acta Neuropathol* 2010;120:585-592

Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? *Future Oncol* 2010;6:1407-1414

Weller M, Wick W. Nanotechnologie in der Neuro-Onkologie: eine Herausforderung für die evidenzbasierte Medizin. *Akt Neurol* 2010;37:382-383

Stupp R, Hegi M, Weller M. Neuro-oncology, a decade of temozolomide and beyond. *Expert Rev Anticancer Ther* 2010;10:1675-1677

Wick W, Roth P, Wick A, Weller M. What is new in Neurooncology? *Akt Neurol* 2010;37:454-460

Stupp R, Weller M. 2010: neuro-oncology is moving! *Curr Opin Neurol* 2010;23:553-555

Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. *Curr Opin Neurol* 2010;23:597-602

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, Grabenbauer GG, Ochsenein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krüger S, Picard M, Weller M. Reply to M.C. Chamberlain. *J Clin Oncol* 2010;28:e696-e697

2011

Weller M, Wick W. "Nanomania" ante portas of neurooncology? *J Neuro-Oncol* 2011;104:613-614

Tabatabai G, Weller M. Glioblastoma stem cells. *Cell Tissue Res* 2011;343:459-465

Tabatabai G, Tonn JC, Stupp R, Weller M. The role of integrins in glioma biology and anti-glioma therapies. *Curr Pharm Design* 2011;17:2402-2410

Korfel A, Thiel E, Martus P, Weller M. Whole-brain radiotherapy in primary CNS lymphoma. *Lancet Oncol* 2011;12:119-120

Preusser M, De Ribaupierre S, Wöhrer A, Erridge SC, Hegi M, Weller M, Stupp R. Current concepts and management of glioblastoma. *Ann Neurol* 2011;70:9-21

Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. *Curr Neurol Neurosci Rep* 2011;11:305-312

Weller M, Wick W. Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma? *Neuro-Oncol* 2011;13:365-366

Wick W, Weller M. Trabedersen to target transforming growth factor- β : when the journey is not the reward. *Neuro-Oncol* 2011;13:559-560

Wick W, Weller M, Weiler M, Batchelor T, Yung AWK, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. *Neuro-Oncol* 2011;13:566-579

Weller M. Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials. *Neuro-Oncol* 2011;13:565

Weller M. Novel diagnostic and therapeutic approaches to malignant glioma. *Swiss Med Weekly* 2011;141:w13210

Tabatabai G, Wick W, Weller M. Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach. *Discovery Medicine* 2011;11:529-536

Linnebank M, Moskau S, Semmler A, Widman G, Stoffel-Wagner B, Weller M, Elger CE. Vitamin B12, folate and hyperhomocysteinemia in patients with epilepsy. Reply. *Ann Neurol* 2011;69:1068

Weller M, Wick W, von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. *Glia* 2011;59:1200-1204

Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide

$\alpha v\beta 3$ and $\alpha v\beta 5$ integrin inhibitor in development for glioblastoma and other malignancies. *Future Oncol* 2011;7:339-354

Weller M, Stupp R. Clinical trials in Neuro-Oncology: one step forward, two steps back? *Curr Opin Neurol* 2011;24:597-598

Weller M, Platten M, Roth P, Wick W. Geriatric neuro-oncology: from mythology to biology. *Curr Opin Neurol* 2011; 24:599-604

2012

Weller M. Angiogenesis inhibition: quo vadis? *Neuro-Oncology* 2012;14:1315

Essig M, Anzalone N, Combs SE, Dörfler A, Lee SK, Picozzi P, Rovira A, Weller M, Law M. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. *Am J Neuroradiol* 2012;33:803-817

Brandes AA, Franceschi E, Gorlia T, Wick W, Jacobs AH, Baumert BG, van den Bent M, Weller M, Stupp R; On behalf of European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. *Eur J Cancer* 2012;48:896-903

Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? *Cancer J* 2012;18:40-44

Seystahl K, Weller M. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? *Exp Opin Invest Drugs* 2012;21:605-617

Roth P, Korfel A, Martus P, Weller M. Pathogenesis and management of primary central nervous system lymphoma. *Exp Rev Anticancer Ther* 2012;12:623-633

Tabatabai G, Hegi M, Stupp R, Weller M. Clinical implications of molecular neuropathology and biomarkers for malignant glioma. *Curr Neurol Neurosci Rep* 2012;12:302-307

Weller M. More on the immune privilege of glioblastoma. *Neuro-Oncology* 2012;14:527-528

Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, Van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. *Lancet Oncol* 2012;13:e196-204

Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gerloff C, Gold R, Hacke W, Hufschmidt A, Mattle HP, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Kopp IB, Olma M, Heuschmann P. Wie entstehen die Leitlinien der Deutschen Gesellschaft für Neurologie? *Aktuel Neurol* 2012;39:525-529

Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? *Lancet Oncol* 2012;13:e375-e382

Weller M. Microglia: a novel treatment target in gliomas. *Neuro-Oncology* 2012;14:957

Weller M, Stupp R, Hegi ME, Van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing in malignant glioma patients in clinical practice. *Neuro-Oncology* 2012;14:iv100-iv108

Weller M, Stupp R. Prime time for molecular marker diagnostics in Neuro-Oncology. *Curr Opin Neurol* 2012;25:743-744

Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in

glioblastoma. *Curr Opin Neurol* 2012;25:774–779

2013

Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, Van den Bent MJ. Optimal management of elderly patients with glioblastoma. *Cancer Treat Rev* 2013;39:350-357

Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? *Neuro-Oncology* 2013;15:4-27

Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. *Lancet Oncol* 2013;14:e370-e379

Eisele G, Weller M. Targeting apoptosis pathways in glioblastoma. *Cancer Lett* 2013;332:335-345

Maercker A, Perkonigg A, Preisig M, Schaller K, Weller M. The costs of disorders of the brain in Switzerland. An update from the European Brain Council study for 2010. *Swiss Med Weekly* 2013;143:w13751

Weller M. Assessing the MGMT status in glioblastoma: one step forward, two steps back? *Neuro-Oncology* 2013;15:253-254

Riemenschneider MJ, Louis DN, Weller M, Hau P. Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach. *Acta Neuropathol* 2013;126:21-37

Weller M. Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma? *Neuro-Oncology* 2013;15:809-810

Weller M, Yung WK. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. *Neuro-Oncology* 2013;15:971

Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. *Curr Treat Options Oncol* 2013;14:505-513

Mohme M, Neidert MC, Regli L, Weller M, Martin M. Immunological challenges for peptide-based immunotherapy in glioblastoma. *Cancer Treat Rev* 2014;40:248-258

Roth P, Regli L, Tonder M, Weller M. Tumor-associated edema in brain cancer patients: pathogenesis and management. *Expert Review Anticancer Ther* 2013;13:1319-1325

Tabatabai G, Stupp R, Wick W, Weller M. Malignant astrocytoma in elderly patients: where do we stand? *Curr Opin Neurol* 2013;26:693-700

2014

Weller M, Soffietti R, Brada M. The legend of CMV and glioblastoma lives on. *Neuro-Oncology* 2014;16:266

Weller M, Wick W. Improving outcome in newly diagnosed malignant glioma. *Nat Rev Neurol* 2014;10:68-70

Roth P, Stupp R, Eisele G, Weller M. Treatment of primary CNS lymphoma. *Curr Treat Options Neurol* 2014;16:277

Weller M, Van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W, for the European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO Guideline on the Diagnosis and Treatment of Malignant Glioma. *Lancet Oncol* 2014;15:e395-403

Wick W, Weller M, Van den Bent M, Sanson M, Weiler M, Von Deimling A, Plass C, Hegi M, Platten M, Reifenberger R. MGMT testing - the challenges for biomarker-based glioma treatment. *Nature Rev Neurol* 2014;10:372-385

Stupp R, Weller M. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. *Neuro-Oncology* 2014;16:765-767

Weller M. The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. *Neuro-Oncology* 2014;16:1035-1036

Batchelor TT, Reardon DA, De Groot J, Wick W, Weller M. Anti-angiogenic therapy for glioblastoma: current status and future prospects. *Clin Cancer Res* 2014;20:5612-5619

Weller M. Primary central nervous system lymphoma in the elderly. *Oncol Res Treat* 2014;37:376-377

Roth P, Weller M. Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. *Neuro-Oncology* 2014;16:viii14-viii19

Langen KJ, Tonn JC, Weller M, Galldiks N. Letter to the Editor: The role of imaging in the management of progressive glioblastoma. *J Neurooncol* 2014;120:665-666

Stupp R, Picard M, Weller M. Does cilengitide deserve another chance?-Authors' reply. *Lancet Oncol* 2014;15:e585-586

2015

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CMF, Ferreri AJM, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M, for the European Association for Neuro-Oncology (EANO) Task Force on Primary CNS Lymphoma. EANO Guideline for the diagnosis and treatment of primary CNS lymphoma in immunocompetent patients. *Lancet Oncol* 2015;16:e322-332

Roth P, Weller M. Chemotherapie von Hirntumoren bei Erwachsenen. *Nervenarzt* 2015;86:495-508

Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. *Neuro-Oncol Pract* 2015;2:6-12

Preusser M, Weller M. Brain metastasis research: a late awakening. *Chin Clin Oncol* 2015;4:17

Roth P, Weller M. Management of neoplastic meningitis. *Chin Clin Oncol* 2015;4:26

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister S, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. *Nat Rev Dis Primers* 2015;1:5017

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, Van den Bent MJ, Chang S, Yung WKA, Cloughesy TF, Wen PY, Gilbert MR, and the Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus Recommendations for a Standardized Brain Tumor Imaging Protocol (BTIP) in Clinical Trials. *Neuro-Oncology* 2015;17:1188-1198

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes A, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope W, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy Response Assessment in Neuro-Oncology (iRANO): A Report of the RANO Working Group. *Lancet Oncol* 2015;16:e534-542

Wick W, Weller M. Neuroonkologie. *Nervenarzt* 2015;86:671

Reardon DA, Weller M. Cancer immunology and immunotherapy for CNS tumors. Introduction. *Neuro-Oncology* 2015;17 Suppl 7:vii1

Reardon DA, Weller M. Dedication: Andrew T. Parsa. *Neuro-Oncology* 2015;17 Suppl 7:vii2

Nduom EK, Weller M, Heimberger A. Immunosuppressive mechanisms in glioblastoma. *Neuro-Oncology* 2015;17 Suppl 7:vii9-vii14

Wirsching HG, Happold C, Roth P, Weller M. Management of diffusely infiltrating glioma in the elderly. *Curr Opin Oncol* 2015;27:502-509

Baron R, Ferriero D, Frisoni GB, Bettegowda C, Gokaslan ZL, Kessler JA, Vezzani A, Waxman S, Jarius S, Wildemann B, Weller M. Neurology - the next 10 years. *Nature Rev Neurol* 2015;11:658-664

Happold C, Weller M. New insights into acquired temozolomide resistance in glioblastoma? *Brain* 2015;138:3468-3470

Weiss T, Weller M, Roth P. Immunotherapy for glioblastoma: concepts and challenges. *Curr Opin Neurol* 2015;28:639-646

Preusser M, Berghoff AS, Wick W, Weller M. PD-L1: emerging biomarker in glioblastoma? *Clin Neuropathol* 2015;34:313-321

2016

Seystahl K, Wick W, Weller M. Therapeutic options in recurrent glioblastoma - an update. *Crit Rev Oncol Hematol* 2016;99:389-408

Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M. Therapy for secondary CNS involvement in malignant lymphomas: no standard yet! *J Clin Oncol* in press

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, La Fougère C, Pope W, Law I, Arbizu J, Chamberlain M, Vogelbaum MA, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology (RANO) Working Group and European Association for Neuro-Oncology (EANO) Recommendations for the Clinical Use of PET Imaging in Gliomas. *Neuro-Oncology* in press

Seystahl K, Gramatzki D, Roth P, Weller M. Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives. *Exp Opin Pharmacother* in press

Roth P, Preusser M, Weller M. Immunotherapy of brain cancer. *Oncol Res Treatment* in press

C. Chapters in Books and Conference Proceedings

1989

Weller M, Wiedemann P, Zilles K, Heimann K. Macrophages, fibronectin, transferrin – major pathogenetic factors in proliferative vitreoretinopathy. In Heimann K, Wiedemann P (Hrsg.). Proliferative Vitreoretinopathy (PVR). Kaden, Köln, 1989, 104-108

Moter H, Wiedemann P, Weller M, Heimann K, Zilles K. Characterization of vitreous proteins by isoelectric focusing. In Heimann K, Wiedemann P (Hrsg.). Proliferative Vitreoretinopathy (PVR). Kaden, Köln, 1989, 113-117

1990

Hartmann C, Wiedemann P, Gothe K, Weller M, Heimann K. Nachstarprävention durch endokapsuläre Daunomycinapplikation. In Freyler H, Skorpik CH, Grasl M (Hrsg.). 3. Kongress der Deutschen Gesellschaft für Intraokularlinsenimplantation. Springer, Wien New York, 1990, 414-422

1991

Schabet M, Melms A, Weller M, Wiethölter H. Autochthone IgG-Bildung bei Meningeosis neoplastica. Verhandlungen der Deutschen Gesellschaft für Neurologie 1991;6:329-330

Sommer N, Weller M, Petersen D, Wiethölter H, Dichgans J. Neurosarkoidose. Neuere diagnostische Möglichkeiten und Falldarstellung. Verhandlungen der Deutschen Gesellschaft für Neurologie 1991;6:608-609

Weller M, Sommer N, Stevens A, Wiethölter H, Dichgans J. Liquor und Serumfibronectin bei entzündlichen und neoplastischen Erkrankungen des Zentralnervensystems. Verhandlungen der Deutschen Gesellschaft für Neurologie 1991;6:606-607

Weller M, Stevens A, Sommer N, Melms A, Dichgans J, Wiethölter H. Monitoring of disease activity in multiple sclerosis by cerebrospinal fluid interleukin determination. Proceedings of the ECTRIMS Symposium, Tübingen 1990. Elsevier, Amsterdam, 1991, 117-122

1992

Weller M, Wilhelm H, Sommer N, Dichgans J, Wiethölter H. Das Ross-Syndrom. Pupillotonie, Hyporeflexie und segmentale Anhidrose. In Huffmann G, Braune HJ (Hrsg.). Läsionen des peripheren Nervensystems. Einhorn, Reinbeck, 1992, 253-256

1994

Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Induktion von programmiertem Zelltod und Apoptose humaner maligner Gliomzellen durch Anti-Fas/APO-1/CD95-Antikörper. Verhandlungen der Deutschen Gesellschaft für Neurologie 1994;8:664-666

Sommer N, Löschnann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmüller A, Dichgans J, Martin R. Der Phosphodiesterase IV Inhibitor Rolipram supprimiert die klinischen Symptome der experimentell autoimmunen Enzephalomyelitis. Verhandlungen der Deutschen Gesellschaft für Neurologie 1994;8:713-715

1995

Kornhuber J, Weller M. Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In Fog R, Gerlach J, Hemmingsen R, Krogsgaard-Larsen P, Thaysen JH (Hrsg.). Schizophrenia. An integrated view. Alfred Benzon Symposium 38. Munksgaard, Kopenhagen, 1995, 314-325

Fontana A, Constam DB, Frei K, Koedel U, Pfister W, Weller M. Cytokines and defense against CNS infection. In Benveniste E, Ransohoff RM (Hrsg.). Cytokines and the CNS: Development, Defense and Disease. CRC Press, Boca Raton, FL, 1995, 187-219

Remé CE, Weller M, Szczesny P, Munz K, Hafezi F, Reinboth JJ, Clausen M. Light-induced apoptosis in the rat retina in vivo: morphological features, threshold and time course. In Anderson RA, La Vail MM, Hollyfield JG (Hrsg.). Degenerative diseases of the retina. Plenum Press, New York, NY, 1995, 19-25

1996

Weller M, Fontana A. Multiple Sklerose. In Peter HH, Pichler WJ (Hrsg.). Klinische Immunologie. 2. Aufl. Urban & Schwarzenberg, München, 1996, 626-633

Zimmermann I, Widmer U, Weller M, Spillmann T, Fontana A. Cogan-Syndrom. In Peter HH, Pichler WJ (Hrsg.). Klinische Immunologie. 2. Aufl. Urban & Schwarzenberg, München, 1996, 872-875

Kornhuber J, Weller M. Die Rolle des glutamatergen Systems beim malignen neuroleptischen Syndrom. Kongressband des DGPPN-Jubiläumskongresses 1992: Peters UH, Schifferdecker M, Krahl A (Hrsg.) 150 Jahre Psychiatrie. Eine vielgestaltige Psychiatrie für die Welt von morgen. Martini, Köln, 1996

Kornhuber J, Weller M. Ursachen und Therapie des malignen neuroleptischen Syndroms. In Feiereis H, Saller R (Hrsg.). 170 neue, noch unveröffentlichte Fragen und Antworten aus der Praxis. Hans Marseille, München, 1996, 173-175

1997

Kornhuber J, Weller M, Riederer P. Which phencyclidine-like N-methyl-D-aspartate receptor antagonists are currently available for clinical use? Bibliotheca Psychiatrica (Proceedings of the CINP Regional Conference Wien 1995) Karger, Basel, 1997, 175-180

Kornhuber J, Weller M. Das maligne neuroleptische Syndrom. Fortbildungsband III der Deutschen Gesellschaft für Neurologie, 1997, W102-106

1998

Schulz JB, Weller M. Prion-Erkrankungen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 536-540

Weller M. Hyperthermie. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 587-594

Schabet M, Weller M. Primäre intrakranielle und spinale Tumoren im Erwachsenenalter. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 645-693

Weller M, Schabet M. Leptomeningeale Metastasen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 722-734

Weller M. Neurogene Störungen von Blasen-, Darm- und Sexualfunktion. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 1998, 1245-1261

Schulz JB, Simons M, von Coelln R, Dichgans J, Weller M. The role of caspases in neuronal cell death. In Kriegelstein J (Hrsg.). Pharmacology of Cerebral Ischemia. Medpharm Scientific Publ., Stuttgart, 1998, 141-150

1999

Klockgether T, Weller M. Trinukleotid-Erkrankungen. In Ganten D, Ruckpaul K (Hrsg.). Handbuch der molekularen Medizin. Springer, Berlin, 1999, Band 5, 67-102

2000

Cavenee WK, Furnari FB, Nagane M, Huang HJS, Newcomb EW, Bigner DD, Weller M, Berens M, Plate KH, Israel MA, Noble MD, Kleihues P. Diffusely infiltrating astrocytomas. In Kleihues P, Cavenee WK (Hrsg.) Pathology and Genetics of Tumors of the Nervous System. IARC Press, Lyon, 2000, 10-21

2001

Roth W, Weller M. Death ligand/death receptor-mediated apoptosis in malignant glioma. In Liao LM, Becker DP, Cloughsey TF, Bigner DD (Hrsg.). Brain Tumor Immunotherapy. Humana Press, Totowa, NJ, 2001, 327-344

Schabet M, Weller M. Hirn- und Rückenmarkstumoren. In Huhn D, Herrmann R (Hrsg.) Medikamentöse Therapie maligner Erkrankungen. Urban & Fischer, München, 2001, 437-471

Weller M. Sein oder Nichtsein: über sinnvolle und unerwünschte Selbstmorde von Gehirnzellen. In Kettenmann H, Gibson M (Hrsg.) Kosmos Gehirn. Neurowissenschaftliche Gesellschaft, Berlin, 2001, 30-31

Weller M. Chemotherapie von Gliomen. Intensivkurs Neurologie. Ärzte-Seminare Karlsruhe. KKA, Holler, Karlsruhe, 2001, 42-46

Weller M. Indikation zur Chemotherapie bei Gliomen. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 74. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2001, 209-211

2002

Weller M. Primäre Hirntumoren. In Riess O, Schöls L (Hrsg.) Neurogenetik. Molekulargenetische Diagnostik neurologischer und psychiatrischer Erkrankungen. Kohlhammer, Stuttgart, 2002, 247-252

Weller M, Wick W, Steinbach JP, Wagenknecht B, Naumann U, Roth W. The role of apoptosis in cancerogenesis and resistance to therapy: lessons from malignant glioma. In Zierhut M, Jager M, Ksander B (Hrsg.) Immunology of ocular tumors. Swets & Zeitlinger Publishers, Sassenheim, 2002, 131-139

Weller M. Therapiekonzepte bei niedergradigen Gliomen. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 75. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2002, 78-80

2003

Weller M, Lehmann-Horn F. Malignant hyperthermia and neuroleptic malignant syndrome. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg.) Course and Treatment of Neurological Disorders. Academic Press, San Diego, CA, 2003, 783-789

Weller M, Thomas DGT. Primary tumors of the central and peripheral nervous system. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg.) Course and Treatment of Neurological Disorders. Academic Press, San Diego, CA, 2003, 827-863

Weller M. Brain metastases from systemic solid tumors. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg.) Course and Treatment of Neurological Disorders. Academic Press, San Diego, CA, 2003, 881-895

Weller M. Leptomeningeal metastasis. In Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C

- (Hrsg.) Course and Treatment of Neurological Disorders. Academic Press, San Diego, CA, 2003, 897-909
- Schulz JB, Weller M. Prion-Erkrankungen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 664-670
- Weller M, Lehmann-Horn F. Maligne Hyperthermie und neuroleptisches malignes Syndrom. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 722-727
- Weller M, Wick W. Primäre intrakranielle und spinale Tumoren. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 776-811
- Weller M. Hirnmetastasen solider extrazerebraler Tumoren. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 829-847
- Wick W, Weller M. Leptomeningeale Metastasierung. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 849-859
- Weller M. Neurogene Störungen von Blasen-, Darm- und Sexualfunktion. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2003, 1408-1424
- Weller M, Schlegel U. Diagnostik. Andere diagnostische Maßnahmen. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 82-83
- Weller M, Westphal M. Grundlagen der speziellen Therapie. Therapiestudien. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 114-115
- Weller M, Schlegel U. Grundlagen der speziellen Therapie. Chemotherapie. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 156-164
- Weller M, Westphal M. Primäre Tumoren des Gehirns und seiner Häute. Anaplastische Astrozytome. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 192-196
- Weller M, Westphal M. Primäre Tumoren des Gehirns und seiner Häute. Glioblastome. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 196-204
- Schlegel U, Weller M. Primäre Tumoren des Gehirns und seiner Häute. Astrozytäre Varianten. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 204-206
- Schlegel U, Weller M. Primäre Tumoren des Gehirns und seiner Häute. Oligodendrogliale Tumoren. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 207-211
- Schlegel U, Weller M. Primäre Tumoren des Gehirns und seiner Häute. Primäre ZNS-Lymphome. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 285-292
- Weller M. Medikamentöse Therapie. Chemotherapie. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 424-425
- Weller M. Medikamentöse Therapie. Hemmung der Signaltransduktion. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 426-427
- Weller M. Medikamentöse Therapie. Apoptoseinduktion. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 427-428
- Schlegel U, Weller M, Westphal M. Medikamentöse Therapie. Ausblick. In Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003, 442

Weller M, Schlegel U, Schackert G. Hirnmetastasen und Meningeosis neoplastica. In Domschke W, Hohenberger W, Meinertz T, Possinger K, Reinhardt D, Tölle R (Hrsg.) Therapie-Handbuch Urban & Fischer, München, 2003, P3-P10

2004

Weller M. Hirnmetastasen und Meningeosis neoplastica. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 77. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2004, 116-119

Weller M. Maligne Gliome. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 77. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2004, 588-590

2005

Weller M. Therapiestrategien bei Meningeosis neoplastica. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 78. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2005, 341-342

Weller M. Neue Studien und Stand der Therapieoptionen beim Glioblastom. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 78. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2005, 624-626

Weller M. Gliomas. In Kettenmann H, Ransom BR (Hrsg.) Neuroglia. Oxford University Press, New York, NY, 2005, 521-531

2006

Weller M, Krauseneck P, Kath R, Kortmann RD, Schmoll HJ. Primäre Hirntumoren bei Erwachsenen. In Schmoll HJ, Höffken K, Possinger K (Hrsg.). Kompendium Internistische Onkologie. Springer, Berlin, 2006, 3219-3260

Weller M, Kortmann RD, Schmoll HJ. Pinealstumoren bei Jugendlichen und Erwachsenen. In Schmoll HJ, Höffken K, Possinger K (Hrsg.). Kompendium Internistische Onkologie. Springer, Berlin, 2006, 3261-3272

Weller M, Schlegel U. Onkologie. In Deuschl G, Reichmann H (Hrsg.) Gerontoneurologie. Thieme, Stuttgart, 2006, S. 193-201

Weller M. Oligodendroglioma. In Tonn JC, Westphal M, Rutka J, Grossman S (Hrsg.) Neuro-Oncology of CNS tumors. Springer, Heidelberg, 2006, 139-144

Steinbach JP, Weller M. Apoptosis pathways and chemotherapy. In Newton HB (Hrsg.) Handbook of Brain Tumor Chemotherapy. Elsevier, San Diego, CA, 2006, 141-154

Rieger J, Weller M. Exploiting apoptosis pathways for glioblastoma therapy. In Debatin KM, Fulda S (Hrsg.) Apoptosis and cancer therapy. Wiley, Weinheim, 2006, 1033-1048

Rössler K, Knosp E, Weller M. Zerebrale raumfordernde Prozesse. In Stefan H, Mamoli B (Hrsg.) Aktuelle Therapie in der Neurologie. Ecomed Medizin, Landsberg/Lech, 2006, VI-1, 1-45

Weller M. Kontroversen bei der Therapie „niedrigmaligner“ Gliome. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 79. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2006, 94-97

Weller M. Maligne Gliome: Aktuelle Therapiestudien in Deutschland. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 79. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2006, 419-421

2007

Diener HC, Weller M. Neurologie. In Gerok W, Huber C, Meinertz T, Zeidler H. (Hrsg.) Die Innere Medizin. Schattauer, Stuttgart, 2007, 1395-1442

Weller M, Müller B, Kortmann RD. Tumoren des Nervensystems. In Seeber S, Schütte J (Hrsg.) Therapiekonzepte Onkologie. Springer, Heidelberg, 2007, 458-487

Weller M, Wick W. New approaches to brain tumor therapy. In Baehring JM, Piepmeier JM (Hrsg.) Brain tumors. Practical guide to diagnosis and treatment. Informa Healthcare New York, NY, 2007, 69-91

Schulz JB, Weller M. Prion-Erkrankungen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 716-722

Weller M, Lehmann-Horn F. Maligne Hyperthermie und neuroleptisches malignes Syndrom. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 780-785

Wick W, Tonn JC, Weller M. Primäre intrakranielle und spinale Tumoren. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 832-867

Wick W, Weller M. Hirnmetastasen. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 885-901

Wick W, Weller M. Meningeosis neoplastica. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 902-910

Gratzke C, Weller M, Stief CG. Neurogene Störungen von Blasen-, Darm- und Sexualfunktion. In Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2007, 1465-1483

Weller M. Wieviele Therapeuten braucht ein Hirntumorpatient? Sonderband Aktuelle Neurologie. Fortbildungsakademie der 80. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2007, 477-478

Weller M. Gehirntumore: mehr Lebensqualität für die Patienten. In Kömpf D (Hrsg.) 100 Jahre Deutsche Gesellschaft für Neurologie. Berlin, 2007, 253-256

Weller M, Novak K. Spinale raumfordernde Prozesse. In Stefan H, Mamoli B (Hrsg.) Aktuelle Therapie in der Neurologie. Ecomed Medizin, Landsberg/Lech, 2007, VI-2.1, 1-14; zusätzlich publiziert in Zeller WJ, Zur Hausen H (Hrsg.) Onkologie. Grundlagen, Diagnostik, Therapie, Entwicklungen 2007, V-2.19, 1-11

Novak K, Weller M. Intraoperatives neurophysiologisches Monitoring bei spinalen neurochirurgischen Eingriffen. In Stefan H, Mamoli B (Hrsg.) Aktuelle Therapie in der Neurologie. Ecomed Medizin, Landsberg/Lech, 2007, VI-2.1, 1-8

2008

Weller M. Einführung in die Erkrankungen des zentralen, peripheren und autonomen Nervensystems. In Letzel S, Nowak D (Hrsg.) Handbuch der Arbeitsmedizin Ecomed Medizin, Landsberg/Lech, 2008, DI-2.1, 1-20

Weller M. Hirntumoren. In Bäumer R, Maiwald A (Hrsg.) Onkologische Pflege. Thieme, Stuttgart, 2008, 301-305

Weller M, Kornhuber J. Neuroleptic malignant syndrome. In Lang F (Hrsg.) Encyclopedia of Molecular Mechanisms of Disease. Springer, Heidelberg, 2008

Weller M. Gliomas. In Lang F (Hrsg.) Encyclopedia of Molecular Mechanisms of Disease. Springer, Heidelberg, 2008

Weller M, Schlegel U. Hirntumoren. In Schwab S, Schellinger P, Werner C, Unterberg A, Hacke W (Hrsg.) Neuro-Intensiv-Buch. Springer, Heidelberg, 2008, 577-588

Weller M. Die Wertigkeit molekularer Marker in der Gliomtherapie. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 81. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2008, 345-346

Naumann U, Weller M. Modulating TGF- β receptor signaling: a novel approach of cancer therapy. In Jakowlew SB (Hrsg.) Transforming growth factor- β in cancer therapy. Vol II. Cancer treatment and therapy. Humana Press, Totowa, NJ, 2008 (ISBN 978-1-58829-715-0)

2009

Wick W, Weller M. Adjuvant therapy. In von Deimling A (Hrsg.) Recent results in cancer research. Gliomas. Springer, Heidelberg, 2009, 141-153

Weller M. Neue Studien bei primären ZNS-Lymphomen. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 82. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2009, 447-448

Weller M. Highlights aus dem Deutschen Gliomnetzwerk. Sonderband Aktuelle Neurologie. Fortbildungsakademie der 82. Jahrestagung der Deutschen Gesellschaft für Neurologie. Thieme, Stuttgart, 2009, 549-550

Weller M, Schlegel U, Schackert G. Hirnmetastasen und Meningeosis neoplastica. In Domschke W, Berger M, Hohenberger W, Meinertz T, Possinger K (Hrsg.) Therapie-Handbuch Urban & Fischer, München, 2009, P3-1-12

2010

Hofer S, Happold C, Weller M. Oligodendroglioma. In Tonn JC, Westphal M, Rutka JT (Hrsg.) Oncology of CNS Tumors, Springer, Heidelberg 2010, 163-169

Jung H, Bremer J, Weller M. Myositis. In Chernajvovsky Y, Robbins PD (Hrsg.) Gene Therapy in Inflammatory and Autoimmune Diseases. Birkhäuser, Springer Basel AG, 2010, 79-90

Weller M. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 10 – Update Hämatologie/Onkologie 2010. Lukon, München, 2010, 555-568

Weller M. Bevacizumab (Avastin®) and malignant glioma: is there a role? In Chen T, Chamberlain MC (Hrsg.) Controversies in Neuro-Oncology - Volume 1: Avastin & Malignant Gliomas. Bentham e-books / Bentham Science Publishers 2010, Chapter 23

2011

Perry JR, Wick W, Weller M. Optimizing the use of alkylators in Neuro-Oncology. American Society of Clinical Oncology (ASCO), Chicago, Educational, 2011

Schackert G, Pinzer T, Kortmann RD, Weller M. Hirntumoren. In Schlag PM, Bamberg M, Jäger D (Hrsg.) Interdisziplinäre Entscheidungswege in der Onkologie. Deutscher Ärzteverlag, Köln, 2011, 41-47

Weller M. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 12 – Update Hämatologie/Onkologie 2011. Lukon, München, 2011, 509-520

Weller M, Schlegel U. Hirntumoren. In Schwab S, Schellinger P, Werner C, Unterberg A, Hacke W (Hrsg.) Neuro-Intensiv-Buch. 2. Auflage Springer, Heidelberg, 2008, 573-584

2012

Roth P, Eisele G, Weller M. Immunology of brain tumors. Handbook of Clinical Neurology. Elsevier, Amsterdam, NL, 2012;104:45-51 (ISBN 978-0-444-52138-5)

Wick W, Tonn JC, Weller M. Primäre intrakranielle und spinale Tumoren. In Brandt T, Diener HC, Gerloff C (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2012, 813-847 (ISBN 978-3-17-021674-7)

Wick W, Winkler F, Westphal M, Weller M. Hirnmetastasen. In Brandt T, Diener HC, Gerloff C (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2012, 862-877

Wick W, Weller M. Meningeosis neoplastica. In Brandt T, Diener HC, Gerloff C (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, 2012, 878-86

Weller M. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 14 – Update Hämatologie/Onkologie 2011. Lukon, München, 2012, 485-495 (ISBN 978-3-933012-23-4)

Sandor P, Weller M. Kopf- und Gesichtsschmerzen sowie Neuralgien. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 220-233

Sandor P, Weller M. Arm- und Beinschmerzen neurogener Art. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 318-331

Schwarz U, Weller M, Lüscher TF. Schwindel und synkopale Zustände. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 941-980

Schwarz U, Weller M, Spinass GA, Kupferschmidt H. Bewusstseinsstörungen und komatöse Zustände. In Battegay E (Hrsg.). Siegenthalers Differenzialdiagnose. Innere Krankheiten – vom Symptom zur Diagnose. Thieme, Stuttgart, 2013, 981-1001

Weller M. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 16 – Update Hämatologie/Onkologie 2013. Lukon, München, 2013, 497-510 (ISBN 978-3-933012-27-2)

2014

Weller M. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 18 – Update Hämatologie/Onkologie 2014. Lukon, München, 2014, 509-520 (ISBN 978-3-933012-32-6)

2015

Weller M, Schlegel U, Schmieder K. Hirntumoren. In Schwab S, Schellinger P, Werner C, Unterberg A, Hacke W (Hrsg.) Neuro-Intensiv-Buch. 3. Auflage. Springer, Heidelberg, 2015, 609-619

Weller M. ZNS-Tumoren. In Petrasch S, Ehninger G (Hrsg.) Colloquium Onkologie 20 – Update Hämatologie/Onkologie 2015. Lukon, München, 2015, 542-552 (ISBN 978-3-933012-34-0)

2016

Tallen G, Mynarek M, von Hoff K, Tischler T, Weller M, Rutkowski S. Diagnostics and diagnosis of

late effects in childhood brain tumour survivors. In Langer T, Beck JD, Bokemeyer C (Hrsg.) Cancer aftercare and late treatment effects in the young. From childhood to early adulthood. 2016, Springer, Heidelberg, in press

Berger MS, Weller M. Preface. Handb Clin Neurol 2016;134:ix

Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol 2016;134:381-97

Books

Weller M, Wiedemann P. Seele und Sehen. Interdisziplinäre Aspekte von Augenheilkunde und Psychiatrie. Deutscher Ärzteverlag, Köln, 1990

Schlegel U, Weller M, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart, 2003

Brötz D, Weller M. Diagnostik und Therapie bei Bandscheibenschäden. Neurologie, Physiotherapie und das McKenzie-Konzept. Thieme, Stuttgart, 2004

Brötz D, Weller M. Bandscheibenleiden. Ihr Aktivprogramm. Trias, Stuttgart, 2006

Schlegel U, Weller M, Westphal M. Neuroonkologische Therapie. Kohlhammer, Stuttgart, 2009

E. Guidelines

Lead author

Interdisziplinäres Tumorzentrum Tübingen. Primäre Hirntumoren und ZNS-Metastasen. 3. Auflage, 2000

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Meningeosis neoplastica. www.neuroonkologie.de, 2001

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Interdisziplinäre Leitlinien für die Diagnostik und Therapie supratentorieller Gliome des Erwachsenenalters. www.neuroonkologie.de, 2001

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Meningeosis neoplastica. Thieme, Stuttgart, 2002, 133-136

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Hirnmetastasen. Thieme, Stuttgart, 2002, 137-140

Interdisziplinäres Tumorzentrum Tübingen. Primäre Hirntumoren und ZNS-Metastasen. 4. Auflage, 2003

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Maligne Gliome. Thieme, Stuttgart, 2003, 434-443

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Hirnmetastasen. Thieme, Stuttgart, 2003, 444-447

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Meningeosis neoplastica. Thieme, Stuttgart, 2003, 448-451

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Diagnostik und Therapie der Gliome des Erwachsenenalters. www.neuroonkologie.de, Zuckschwerdt, München, 2004

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Maligne Gliome. Thieme, Stuttgart, 2005, 662-677

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Hirnmetastasen. Thieme, Stuttgart, 2005, 678-683

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Meningeosis neoplastica. Thieme, Stuttgart, 2005, 684-688

Südwestdeutsches Tumorzentrum / Comprehensive Cancer Center Tübingen. Primäre Hirntumoren und ZNS-Metastasen. 5. Auflage, 2006

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, Weller M, Wiegel T, Hrsg.). Gliome des Erwachsenenalters. Zuckschwerdt, München, 2006, 340-359

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, Weller M, Wiegel T, Hrsg.). Meningeosis neoplastica. Zuckschwerdt, München, 2006, 360-372

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Gliome. Thieme, Stuttgart, 2008, 774-788

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC,

Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Solide Hirnmetastasen. Thieme, Stuttgart, 2008, 789-796

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Spinale Metastasen und Meningeosis neoplastica. Thieme, Stuttgart, 2008, 797-802

Neuroonkologie. Empfehlungen zur Diagnostik, Therapie und Nachsorge (Weller M, Hofer S, Hrsg.). UniversitätsSpital Zürich / Universität Zürich, 2009

Neuroonkologie. Empfehlungen zur Diagnostik, Therapie und Nachsorge (Weller M, Hrsg.). UniversitätsSpital Zürich / Universität Zürich, 2011

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Gliome. Thieme, Stuttgart, 2012, 922-940

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Weimer C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Metastasen und Meningeosis neoplastica. Thieme, Stuttgart, 2012, 941-958

Neuroonkologie. Empfehlungen zur Diagnostik, Therapie und Nachsorge (Weller M, Roth P, Hrsg.). UniversitätsSpital Zürich / Universität Zürich, 2013

Coauthor

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Zerebrale Lymphome. Thieme, Stuttgart, 2002, 128-130

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hacke W, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2002, 227-232

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Hirnmetastasen. www.neuroonkologie.de, 2003

Neuro-Onkologische Arbeitsgemeinschaft (NOA) in der Deutschen Krebsgesellschaft. Leitlinie Primäre ZNS-Lymphome. www.neuroonkologie.de, 2003

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Neurosyphilis. Thieme, Stuttgart, 2003, 253-257

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Zerebrale Lymphome. Thieme, Stuttgart, 2003, 452-454

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2003, 455-460

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Neurosyphilis. Thieme, Stuttgart, 2005, 376-381

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Zerebrale Lymphome. Thieme, Stuttgart, 2005, 689-694

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2005, 695-702

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, Weller M, Wiegel T, Hrsg.). Diagnostische Bildgebung bei Hirntumoren. Zuckschwerdt, München, 2006, 333-339

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, Weller M, Wiegel T, Hrsg.). Primäre ZNS-Lymphome. Zuckschwerdt, München, 2006, 373-378

Deutsche Krebsgesellschaft. Kurzgefasste interdisziplinäre Leitlinien 2006 (Garbe C, Albers P, Beckmann MW, Bokemeyer C, Bootz F, Creutzig U, Drings P, Gabbert HE, Heimpel H, Hohenberger W, Howaldt HP, Kloke M, Schackert G, Schmiegel W, Weller M, Wiegel T, Hrsg.). Zerebrale Metastasen. Zuckschwerdt, München, 2006, 379-393

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Bildgebung bei Hirntumoren. Thieme, Stuttgart, 2008, 766-773

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Primäre ZNS-Lymphome. Thieme, Stuttgart, 2008, 803-808

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2008, 809-816

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Primäre ZNS-Lymphome (PZNSL). Thieme, Stuttgart, 2012, 959-964

Leitlinien für Diagnostik und Therapie in der Neurologie. Deutsche Gesellschaft für Neurologie (Diener HC, Putzki N, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch CW, Weller M, Hrsg.). Paraneoplastische Syndrome. Thieme, Stuttgart, 2012, 966-976